"source","date","assertionType","evidenceType","prefix","exactText","suffix","modality","statementType","comment","drug1Lab","drug1Type","drug1Role","dose1","drug2Lab","drug2Type","drug2Role","dose2","objectRegimens","objectFormulation","objectDuration","preciptRegimens","preciptFormulation","preciptDuration","numOfParticipants","auc","aucType","aucDirection","cl","clType","clDirection","cmax","cmaxType","cmaxDirection","t12","t12Type","t12Direction"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 17:58:31 -0700","DDI-clinical-trial","evidence-supports",". In addition, there was no pharmacodynamic interaction as a result of coadministration of zaleplon and venlafaxine ER.  ","Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve. However, the pharmacodynamics of coadministration of zaleplon and promethazine have not been evaluated. Caution should be exercised when these 2 agents are coadministered.","","ncit:positive","ncit:quantitative","but no change in the area under the plasma concentration-time curve.","promethazine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","25","zaleplon","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","10","SD","Oral","1","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","15","Percent","Decrease","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1a5a93be-7bc3-4714-9308-2fbfb8260e23.html","2016-02-29 15:03:48 -0700","drug-drug-interaction","evidence-supports","Phenothiazines can produce alpha-adrenergic blockade.  ","Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.","","ncit:positive","ncit:Qualitative","Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs","propranolol","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"phenothiazines","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 14:55:51 -0700","drug-drug-interaction","evidence-supports","5.5 Effect of P-gp Inducers and Inhibitors on Dabigatran Exposure   ","The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided [see Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","rifampin reduces exposure to dabigatran","dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","rifampin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 22:55:21 -0400","drug-drug-interaction","evidence-challenges","combinations revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem .  ","Zolpidem tartrate had no effect on digoxin pharmacokinetics and did not affect prothrombin time when given with warfarin in healthy subjects.","","ncit:negative","ncit:Qualitative","did not affect prothrombin time when given with warfarin","Zolpidem","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"warfarin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e9481622-7cc6-418a-acb6-c5450daae9b0.html","2016-04-12 10:48:58 -0700","drug-drug-interaction","evidence-supports","7.2 Strong Dual Inducers of CYP3A4 and P-gp  ","Avoid concomitant use of ELIQUIS with strong dual inducers of CYP3A4 and P-gp (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban [see Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","rifampin will decrease exposure to apixaban","rifampin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"apixaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6.html","2016-03-14 14:01:17 -0700","DDI-clinical-trial","evidence-supports","aripiprazole pharmacokinetics        ","The effects of ABILIFY on the exposures of other drugs are summarized in Figure 21. A population PK analysis in patients with major depressive disorder showed no substantial change in plasma concentrations of fluoxetine (20 mg/day or 40 mg/day), paroxetine CR (37.5 mg/day or 50 mg/day), or sertraline (100 mg/day or 150 mg/day) dosed to steady-state. The steady-state plasma concentrations of fluoxetine and norfluoxetine increased by about 18% and 36%, respectively, and concentrations of paroxetine decreased by about 27%. The steady-state plasma concentrations of sertraline and desmethylsertraline were not substantially changed when these antidepressant therapies were coadministered with aripiprazole.","","ncit:positive","ncit:quantitative","this was a pop pk study","ABILIFY","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","norfluoxetine","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","20-40","Daily","Oral","UNK","UNK","UNK","UNK","UNK","36","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 15:06:41 -0700","DDI-clinical-trial","evidence-supports","is administered 2 hours after dabigatran etexilate .   ","Ketoconazole: Systemic ketoconazole increased dabigatran AUC and Cmax values by 138% and 135%, respectively, after a single dose of 400 mg, and 153%, and 149%, respectively, after multiple daily doses of 400 mg.","","ncit:positive","ncit:quantitative",,"ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","400","dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","SD","Oral","1","UNK","138","Percent","Increase","UNK","UNK","UNK","135","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/50914a46-eab6-4c83-97cf-6ab0234c8126.html","2017-03-15 14:57:45 -0400","drug-drug-interaction","evidence-supports","estazolam is catalyzed by CYP3A. ","While no in vivo drug-drug interaction studies were conducted between estazolam and inhibitors/inducers of CYP3A, compounds that are potent CYP3A inhibitors (such as ketoconazole, itraconazole, nefazodone, fluvoxamine, and erythromycin) would be expected to increase plasma estazolam concentrations and CYP3A inducers (such as carbamazepine, phenytoin, rifampin and barbiturates) would be expected to decrease estazolam concentrations.","","ncit:positive","ncit:Qualitative",,"rifampin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"estazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 16:26:31 -0700","drug-drug-interaction","evidence-supports","7.1 Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems  ","In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. The increases in exposure ranged from 30% to 160%. Significant increases in rivaroxaban exposure may increase bleeding risk [see Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","increases in rivaroxaban exposure","rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","ritonavir","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 16:01:39 -0500","DDI-clinical-trial","evidence-supports","","When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4 fold and peak concentrations increased 1.7 fold. ","Nefazodone","ncit:positive","ncit:quantitative",,"triazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction",".25","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","SD","Oral","1","BID","Oral","UNK","UNK","4","Fold","Increase","UNK","UNK","UNK","1.7","Fold","Increase","4","Fold","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:47:38 -0400","drug-drug-interaction","evidence-supports","7.1 Potential for Other Drugs to Affect LATUDA   ","LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)]. ","","ncit:positive","ncit:Qualitative",,"clarithromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","","LATUDA","dikbD2R:drug-product","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/39a5dae2-49f7-4662-9eac-aa7b4c7807a4.html","2017-03-15 15:18:23 -0400","DDI-clinical-trial","evidence-challenges","measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.   ","Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin. ","","ncit:negative","ncit:quantitative","ENANTIOMER
Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of warfarin","warfarin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","25","Eszopiclone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","3","SD","Oral","1","Daily","Oral","5","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 16:13:29 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. ","Strong inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, erythromycin, and cobicistat-containing products), and grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin. (See CONTRAINDICATIONS, WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics.)","","ncit:positive","ncit:Qualitative","Clarithromycin is a strong inhibitor of CYP3A4 and reduces the elimination of lovastatin","clarithromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"lovastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/aad8b373-0aec-4efb-8e61-3d8114b31127.html","2016-03-30 15:09:14 -0700","drug-drug-interaction","evidence-supports","   7.7 Phenytoin  ","Concomitant administration of fluvastatin and phenytoin increased phenytoin exposures. Patients should continue to be monitored appropriately when fluvastatin therapy is initiated or when fluvastatin dose is changed [see Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","Concomitant fluvastatin increases phenytoin exposure. Details in Section 12 Table 3","phenytoin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","fluvastatin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 16:35:23 -0500","DDI-clinical-trial","evidence-supports","elimination and cause increased blood levels.   ","Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.","","ncit:positive","ncit:quantitative",,"ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","iloperidone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","3","SD","Oral","1","BID","Oral","4","19","57","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d78e9639-6fab-4a78-8b29-6991a18ae6c6.html","2016-02-19 17:46:51 -0500","drug-drug-interaction","evidence-supports","hydroxylase). Approximately 10% of the Caucasian population has reduced activity of this enzyme, so-called “poor” metabolizers. Among other populations the prevalence is not known. Poor metabolizers demonstrate higher plasma concentrations of antipsychotic drugs at usual doses, which may correlate with emergence of side effects. ","In one study of 45 elderly patients suffering from dementia treated with perphenazine, the 5 patients who were prospectively identified as poor P450 2D6 metabolizers had reported significantly greater side effects during the first 10 days of treatment than the 40 extensive metabolizers, following which the groups tended to converge. Prospective phenotyping of elderly patients prior to antipsychotic treatment may identify those at risk for adverse events.    The concomitant administration of other drugs that inhibit the activity of P450 2D6 may acutely increase plasma concentrations of antipsychotics. Among these are tricyclic antidepressants and selective serotonin reuptake inhibitors, e.g., fluoxetine, sertraline and paroxetine. When prescribing these drugs to patients already receiving antipsychotic therapy, close monitoring is essential and dose reduction may become necessary to avoid toxicity. Lower doses than usually prescribed for either the antipsychotic or the other drug may be required.","","ncit:positive","ncit:Qualitative","may acutely increase plasma concentrations of antipsychotics.","paroxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"perphenazine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/aad8b373-0aec-4efb-8e61-3d8114b31127.html","2016-03-31 12:56:52 -0700","drug-drug-interaction","evidence-challenges","Pharmacokinetic data in the pediatric population are not available.   Drug-Drug Interactions:   ","Data from drug-drug interactions studies involving coadministration of gemfibrozil, niacin, itraconazole, erythromycin, tolbutamide or clopidogrel indicate that the PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with any of these drugs.","","ncit:negative","ncit:Qualitative","PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with tolbutamide","tolbutamide","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"fluvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:37:32 -0700","DDI-clinical-trial","evidence-supports","  Fluvoxamine  ","The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. Fluvoxamine and thioridazine should not be coadministered.","","ncit:positive","ncit:quantitative",,"sulforidazine","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","UNK","Fluvoxamine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","25","UNK","Oral","UNK","BID","Oral","7","10","3","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 17:12:19 -0500","DDI-clinical-trial","evidence-supports","does not have enzyme inducing properties, specifically for the following cytochrome P450 isozymes: CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP3A5.   ","Dextromethorphan: A study in healthy volunteers showed that changes in the pharmacokinetics of dextromethorphan (80 mg dose) when a 3 mg dose of iloperidone was co-administered resulted in a 17% increase in total exposure and a 26% increase in the maximum plasma concentrations (Cmax)of dextromethorphan. Thus, an interaction between iloperidone and other CYP2D6 substrates is unlikely.","","ncit:positive","ncit:quantitative",,"dextromethorphan","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","80","iloperidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","3","SD","Oral","1","SD","Oral","1","UNK","17","Percent","Increase","UNK","UNK","UNK","26","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 13:37:19 -0500","DDI-clinical-trial","evidence-challenges","","Phenytoin – Pretreatment for 7 days with 200 mg BID of nefazodone had no effect on the pharmacokinetics of a single 300 mg oral dose of phenytoin. However, due to the nonlinear pharmacokinetics of phenytoin, the failure to observe a significant effect on the single-dose pharmacokinetics of phenytoin does not preclude the possibility of a clinically significant interaction with nefazodone when phenytoin is dosed chronically. ","However, no change in the initial dosage of","ncit:negative","ncit:quantitative",,"nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","Phenytoin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","300","SD","Oral","1","BID","Oral","7","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-02-18 16:49:30 -0700","DDI-clinical-trial","evidence-supports","Drug-Drug Interaction Studies    Fluvoxamine    ","A pharmacokinetic study was conducted in 16 schizophrenic patients who received clozapine under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated about 3-fold compared to baseline steady-state concentrations.","","ncit:positive","ncit:quantitative",,"clozapine N-oxide","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","UNK","fluvoxamine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","14","16","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:50:16 -0400","drug-drug-interaction","evidence-supports","7.1 Potential for Other Drugs to Affect LATUDA   ","LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)]. ","","ncit:positive","ncit:Qualitative",,"verapamil","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","","LATUDA","dikbD2R:drug-product","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/827cf470-485d-4925-85f2-8933a6dea830.html","2016-03-14 17:27:36 -0400","drug-drug-interaction","evidence-supports","   Drug Interactions  ","Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene. Patients receiving these drugs should be observed for signs of reduced thiothixene effectiveness4,5.","","ncit:positive","ncit:Qualitative","carbemazepine found to significantly increase the clearance of thiothixene","carbamazepine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"thiothixene","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 16:29:38 -0500","DDI-clinical-trial","evidence-challenges","may be necessary when coadministered with nefazodone .  ","Lorazepam – When lorazepam (2 mg BID) and nefazodone (200 mg BID) were coadministered to steady state, there was no change in any pharmacokinetic parameter for either drug compared to each drug administered alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.","","ncit:negative","ncit:quantitative",,"Lorazepam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","5","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","SD","Oral","1","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:34:55 -0700","drug-drug-interaction","evidence-supports","potentiated the cognitive and motor effects of alcohol in a clinical trial in subjects with selected psychotic disorders, and alcoholic beverages should be limited while taking quetiapine .  ","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.)","","ncit:positive","ncit:Qualitative","quetiapine exposure is increased by CYP3A4 inhibitors","indinavir","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"Quetiapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/aad8b373-0aec-4efb-8e61-3d8114b31127.html","2016-03-31 12:56:20 -0700","drug-drug-interaction","evidence-challenges","Pharmacokinetic data in the pediatric population are not available.   Drug-Drug Interactions:   ","Data from drug-drug interactions studies involving coadministration of gemfibrozil, niacin, itraconazole, erythromycin, tolbutamide or clopidogrel indicate that the PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with any of these drugs.","","ncit:negative","ncit:Qualitative","PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with erythromycin","erythromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"fluvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:50:16 -0400","drug-drug-interaction","evidence-supports","7.1 Potential for Other Drugs to Affect LATUDA   ","LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)]. ","","ncit:positive","ncit:Qualitative",,"LATUDA","dikbD2R:drug-product","dikbD2R:object-drug-of-interaction",,"diltiazem","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:52:49 -0700","DDI-clinical-trial","evidence-challenges","","Coadministration of aspirin 150 mg/day with multiple daily doses of BRINTELLIX had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin and salicylic acid [see Drug Interactions (7.4)].","","ncit:negative","ncit:quantitative",,"salicylic acid","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","150","BRINTELLIX","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","Daily","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNKUNUNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 16:16:27 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. ","Strong inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, erythromycin, and cobicistat-containing products), and grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin. (See CONTRAINDICATIONS, WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics.)","","ncit:positive","ncit:Qualitative","Nefazodone is a strong inhibitor of CYP3A4 and reduces the elimination of lovastatin","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"lovastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 16:06:57 -0700","drug-drug-interaction","evidence-challenges","Impact of Dabigatran on Other Drugs  ","In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine.","","ncit:negative","ncit:Qualitative","dabigatran did not meaningfully alter the pharmacokinetics of clopidogrel","dabigatran","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clopidogrel","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/aad8b373-0aec-4efb-8e61-3d8114b31127.html","2016-03-31 12:55:51 -0700","drug-drug-interaction","evidence-challenges","Pharmacokinetic data in the pediatric population are not available.   Drug-Drug Interactions:   ","Data from drug-drug interactions studies involving coadministration of gemfibrozil, niacin, itraconazole, erythromycin, tolbutamide or clopidogrel indicate that the PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with any of these drugs.","","ncit:negative","ncit:Qualitative","PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with itraconazole","itraconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"fluvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 18:14:59 -0700","DDI-clinical-trial","evidence-challenges","Drugs with a Narrow Therapeutic Index  ","Digoxin: Zaleplon (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days).","","ncit:negative","ncit:quantitative","Zaleplon did not affect the pharmacokinetic s of digoxin","Zaleplon","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","10","digoxin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction",".375","QD","Oral","8","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:41:32 -0400","drug-drug-interaction","evidence-supports","","Valproate: It is not necessary to adjust the LATUDA dose when used concomitantly with valproate. A dedicated drug-drug interaction study has not been conducted with valproate and LATUDA. Based on pharmacokinetic data from the bipolar depression studies valproate levels were not affected by lurasidone, and lurasidone concentrations were not affected by valproate. ","","ncit:negative","ncit:Qualitative",,"valproate","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"lurasidone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 16:02:33 -0700","drug-drug-interaction","evidence-challenges","digoxin plasma concentrations .   ","Oral Hypoglycemic Agents: In pharmacokinetic studies of MEVACOR in hypercholesterolemic non-insulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide (see CLINICAL PHARMACOLOGY, Clinical Studies).","","ncit:negative","ncit:Qualitative","There was no drug interaction with concomitant lovastatin and chlorpropamide (see CLINICAL PHARMACOLOGY, Clinical Studies)","MEVACOR","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"chlorpropamide","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:47:38 -0400","drug-drug-interaction","evidence-supports","7.1 Potential for Other Drugs to Affect LATUDA   ","LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)]. ","","ncit:positive","ncit:Qualitative",,"LATUDA","dikbD2R:drug-product","dikbD2R:object-drug-of-interaction",,"voriconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 16:11:00 -0500","DDI-clinical-trial","evidence-supports","    Alprazolam   ","When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2 fold.","","ncit:positive","ncit:quantitative",,"alprazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","1","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","BID","Oral","UNK","BID","Oral","UNK","UNK","2","Fold","Increase","UNK","UNK","UNK","2","Fold","Increase","2","Fold","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1a5a93be-7bc3-4714-9308-2fbfb8260e23.html","2016-02-29 17:07:32 -0500","drug-drug-interaction","evidence-supports","Phenothiazines can produce alpha-adrenergic blockade.  ","Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.","","ncit:positive","ncit:Qualitative","Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs","phenothiazines","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"propranolol","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 16:00:52 -0700","drug-drug-interaction","evidence-challenges","digoxin plasma concentrations .   ","Oral Hypoglycemic Agents: In pharmacokinetic studies of MEVACOR in hypercholesterolemic non-insulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide (see CLINICAL PHARMACOLOGY, Clinical Studies).","","ncit:negative","ncit:Qualitative","There was no drug interaction with concomitant lovastatin and glipizide or with chlorpropamide (see CLINICAL PHARMACOLOGY, Clinical Studies).","MEVACOR","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"glipizide","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:19:31 -0700","drug-drug-interaction","evidence-supports","","Reduced cytochrome P450 2D6 isozyme activity drugs that inhibit this isozyme (e.g., fluoxetine and paroxetine) and certain other drugs (e.g., fluvoxamine, propranolol, and pindolol) appear to appreciably inhibit the metabolism of thioridazine. The resulting elevated levels of thioridazine would be expected to augment the prolongation of the QTc interval associated with thioridazine and may increase the risk of serious, potentially fatal, cardiac arrhythmias, such as Torsades de pointes type arrhythmias."," Such an increased risk may result also from the additive effect of coadministering","ncit:positive","ncit:Qualitative","appear to appreciably inhibit the metabolism of thioridazine and result in elevated levels of thioridazine","thioridazine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7d1a9689-23c8-44ef-a474-8c607e13d794.html","2017-03-16 11:26:02 -0400","drug-drug-interaction","evidence-supports",", plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.  ","In 5 other schizophrenic patients treated with haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations. Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.","","ncit:positive","ncit:Qualitative","DELETE","haloperidol","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","rifampin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:17:25 -0400","DDI-clinical-trial","evidence-supports","metabolite 1-pyrimidinylpiperazine.  ","With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%).","","ncit:positive","ncit:quantitative","DELETE","hydroxynefazodone","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","250","buspirone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","5","BID","Oral","UNK","BID","Oral","UNK","UNK","17","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:50:16 -0400","drug-drug-interaction","evidence-supports","7.1 Potential for Other Drugs to Affect LATUDA   ","LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)]. ","","ncit:positive","ncit:Qualitative",,"LATUDA","dikbD2R:drug-product","dikbD2R:object-drug-of-interaction",,"erythromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 16:06:27 -0700","drug-drug-interaction","evidence-challenges","Impact of Dabigatran on Other Drugs  ","In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine.","","ncit:negative","ncit:Qualitative","dabigatran did not meaningfully alter the diclofenac","diclofenac","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","dabigatran","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:37:29 -0700","drug-drug-interaction","evidence-supports","concomitantly with drugs that are inducers or inhibitors of these enzymes.   CYP1A2 Inhibitors   ","Concomitant use of CLOZARIL and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the CLOZARIL dose to one-third of the original dose when CLOZARIL is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The CLOZARIL dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued [see Dosage and Administration (2.6), Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","ciprofloxacin can increase clozapine levels","clozapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","ciprofloxacin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2017-03-16 18:03:34 -0400","DDI-clinical-trial","evidence-supports"," — ","Single doses of olanzapine did not affect the pharmacokinetics of imipramine or its active metabolite desipramine.","","ncit:negative","ncit:quantitative",,"olanzapine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","imipramine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/309f8ac3-a3fd-4313-96aa-7f21fa9cd646.html","2016-05-10 13:11:45 -0400","DDI-clinical-trial","evidence-challenges","  12.4 Drug Interactions  ","Bupropion (a CYP2B6 substrate): Co-administration of a single dose of 150 mg Bupropion Hydrochloride XL with steady state quazepam did not significantly affect the AUC and Cmax of bupropion or its primary metabolite, hydroxybupropion.","","ncit:negative","ncit:quantitative","did not significantly affect the AUC and Cmax of bupropion or its primary metabolite, hydroxybupropion.","quazepam","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","hydroxybupropion","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","150","SD","Oral","1","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 14:34:19 -0500","DDI-clinical-trial","evidence-supports"," —"," Carbamazepine therapy (200 mg bid) causes an approximately 50% increase in the clearance of olanzapine. ","This increase is likely due to the fact that","ncit:positive","ncit:quantitative",,"olanzapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","Carbamazepine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","UNK","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","50","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/50914a46-eab6-4c83-97cf-6ab0234c8126.html","2017-03-15 14:49:47 -0400","DDI-clinical-trial","evidence-challenges","Drug interaction with fluoxetine  ","A multiple-dose study was conducted to assess the effect of fluoxetine 20 mg BID on the pharmacokinetics of estazolam 2 mg QHS after seven days. The pharmacokinetics of estazolam (Cmax and AUC) were not affected during multiple-dose fluoxetine, suggesting no clinically significant pharmacokinetic interaction.","","ncit:positive","ncit:quantitative","pharmacokinetics of estazolam (Cmax and AUC) were not affected","estazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","2","fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","QD","Oral","7","BID","Oral","7","UNK","unchanged","UNK","UNK","UNK","UNK","UNK","unchanged","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2017-03-16 18:03:34 -0400","DDI-clinical-trial","evidence-supports","    Imipramine — ","Single doses of olanzapine did not affect the pharmacokinetics of imipramine or its active metabolite desipramine.","","ncit:negative","ncit:quantitative",,"olanzapine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","desipramine","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","SD","Oral","1","UNK","UNKUNUNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 16:37:25 -0700","DDI-clinical-trial","evidence-supports","exposure may increase bleeding risk.    ","Ketoconazole (combined P-gp and strong CYP3A4 inhibitor): Steady-state rivaroxaban AUC and Cmax increased by 160% and 70%, respectively. Similar increases in pharmacodynamic effects were also observed.","","ncit:positive","ncit:quantitative",,"rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","Ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","160","Percent","Increase","UNK","UNK","UNK","70","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 16:08:16 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. ","Strong inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, erythromycin, and cobicistat-containing products), and grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin. (See CONTRAINDICATIONS, WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics.)","","ncit:positive","ncit:Qualitative","Ketoconazole is a strong inhibitor of CYP3A4 and reduces the elimination of lovastatin","ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"lovastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 16:26:49 -0500","DDI-clinical-trial","evidence-challenges"," This change is of unknown clinical significance."," Pharmacodynamic effects of haloperidol were generally not altered significantly. There were no changes in the pharmacokinetic parameters for nefazodone",". Dosage adjustment of","ncit:negative","ncit:quantitative",,"haloperidol","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","5","nefazodone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","200","BID","Oral","UNK","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 16:22:15 -0700","drug-drug-interaction","evidence-supports","","Results from drug interaction studies and population PK analyses from clinical studies indicate coadministration of XARELTO with a combined P-gp and strong CYP3A4 inducer (e.g., rifampicin, phenytoin) decreased rivaroxaban exposure by up to 50%."," Similar decreases in pharmacodynamic effects were also observed. These decreases in exposure to","ncit:positive","ncit:Qualitative","decreased rivaroxaban exposure by up to 50%.","rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","phenytoin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7d1a9689-23c8-44ef-a474-8c607e13d794.html","2017-03-16 11:25:24 -0400","DDI-clinical-trial","evidence-supports","As with other antipsychotic agents, it should be noted that haloperidol may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.  ","In a study of 12 schizophrenic patients coadministered haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.","","ncit:positive","ncit:quantitative","plasma haloperidol levels were decreased by a mean of 70%","haloperidol","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","Unk","rifampin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","Unk","UNK","UNK","Unk","UNK","UNK","Unk","12","70","Percent","Decrease","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/309f8ac3-a3fd-4313-96aa-7f21fa9cd646.html","2016-05-10 10:09:49 -0700","DDI-clinical-trial","evidence-challenges","  12.4 Drug Interactions  ","Bupropion (a CYP2B6 substrate): Co-administration of a single dose of 150 mg Bupropion Hydrochloride XL with steady state quazepam did not significantly affect the AUC and Cmax of bupropion or its primary metabolite, hydroxybupropion.","","ncit:negative","ncit:quantitative","did not significantly affect the AUC and Cmax of bupropion","quazepam","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","Bupropion","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","150","SD","Oral","1","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/39a5dae2-49f7-4662-9eac-aa7b4c7807a4.html","2016-05-09 19:27:24 -0400","DDI-clinical-trial","evidence-supports","","Eszopiclone and lorazepam decreased each other's Cmax by 22%. ","Coadministration of","ncit:positive","ncit:quantitative",,"lorazepam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","Eszopiclone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","22","Percent","Decrease","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 15:20:54 -0500","drug-drug-interaction","evidence-supports","    Immunosuppressive Agents   ","There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. Both cyclosporine and tacrolimus are substrates of CYP3A4, and nefazodone is known to inhibit this enzyme. If either cyclosporine or tacrolimus is administered with nefazodone, blood concentrations of the immunosuppressive agent should be monitored and dosage adjusted accordingly.","","ncit:positive","ncit:Qualitative","eports of increased blood concentrations","cyclosporine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 15:14:12 -0500","drug-drug-interaction","evidence-supports","are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.  ","Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.","","ncit:positive","ncit:Qualitative","small decreases in the steady-state plasma concentrations which are considered not to be of clinical significance.","mCPP","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","","Lithium","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c6e131fe-e7df-4876-83f7-9156fc4e8228.html","2016-03-14 15:25:58 -0700","DDI-clinical-trial","evidence-supports","TABLE 3. Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin           ","Co-administered drug and dosing regimen  Atorvastatin   Dose (mg)  Change in AUC*  Change in Cmax*    *      Data given as x-fold change represent a simple ratio between co-administration and atorvastatin alone (i.e., 1-fold = no change). Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change).   †      See Sections 5.1 and 7 for clinical significance.   ‡      The dose of saquinavir plus ritonavir in this study is not the clinically used dose. The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, caution should be applied and the lowest dose necessary should be used.   §      Greater increases in AUC (up to 2.5 fold) and/or Cmax (up to 71%) have been reported with excessive grapefruit consumption (≥ 750 mL – 1.2 liters per day).   ¶      Single sample taken 8–16 h post dose.   #      Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.     †Cyclosporine 5.2 mg/kg/day, stable dose  10 mg QD for 28 days  ↑ 8.7 fold  ↑ 10.7 fold  †Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days  10 mg, SD  ↑ 9.4 fold  ↑ 8.6 fold  †Telaprevir 750 mg q8h, 10 days  20 mg, SD  ↑ 7.88 fold  ↑ 10.6 fold","","ncit:positive","ncit:quantitative",,"atorvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","10","Telaprevir","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","750","SD","Oral","1","Q8","Oral","10","UNK","7.88","Fold","Increase","UNK","UNK","UNK","10.6","Fold","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html","2015-11-29 18:49:20 -0500","DDI-clinical-trial","evidence-challenges","is not recommended.   Digoxin   ","Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin. Dose adjustment for digoxin is not recommended.","","ncit:negative","ncit:quantitative",,"digoxin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","Risperidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",".25","UNK","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/39a5dae2-49f7-4662-9eac-aa7b4c7807a4.html","2016-05-09 19:39:00 -0400","drug-drug-interaction","evidence-challenges","","Lorazepam: Coadministration of single doses of eszopiclone and lorazepam did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug. The lack of a drug interaction following single-dose administration does not predict the complete absence of a pharmacodynamic effect following chronic administration. ","","ncit:negative","ncit:Qualitative","Coadministration of single doses of eszopiclone and lorazepam did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug","lorazepam","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"eszopiclone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:42:38 -0400","DDI-clinical-trial","evidence-supports","Interaction With Triazolobenzodiazepines  ","Interaction studies of nefazodone with two triazolobenzodiazepines, i.e., triazolam and alprazolam, metabolized by cytochrome P450 3A4, have revealed substantial and clinically important increases in plasma concentrations of these compounds when administered concomitantly with nefazodone","","ncit:positive","ncit:quantitative","DELETE","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","alprazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/fdbfe194-b845-42c5-bb87-a48118bc72e7.html","2016-03-31 15:44:32 -0400","drug-drug-interaction","evidence-supports","","In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively. ","With other statins, clinically evident bleeding and/or increased","ncit:positive","ncit:Qualitative","simvastatin modestly increased INR from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies respectively.","coumarin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","simvastatin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 16:08:19 -0700","drug-drug-interaction","evidence-challenges","Impact of Dabigatran on Other Drugs  ","In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine.","","ncit:negative","ncit:Qualitative","dabigatran did not meaningfully alter the pharmacokinetics of pantoprazole","pantoprazole","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","dabigatran","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 16:05:56 -0700","drug-drug-interaction","evidence-challenges","Impact of Dabigatran on Other Drugs  ","In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine.","","ncit:negative","ncit:Qualitative","dabigatran did not meaningfully alter the pharmacokinetics of clarithromycin","dabigatran","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clarithromycin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 15:26:04 -0700","DDI-clinical-trial","evidence-supports","","Verapamil: When dabigatran etexilate was coadministered with oral verapamil, the Cmax and AUC of dabigatran were increased. The extent of increase depends on the formulation of verapamil and timing of administration. If verapamil is present in the gut when dabigatran is taken, it will increase exposure to dabigatran with the greatest increase observed when a single dose of immediate-release verapamil is given one hour prior to dabigatran (AUC increased by a factor of 2.4). If verapamil is given 2 hours after dabigatran, the increase in AUC is negligible."," In the population pharmacokinetics study from RE-LY, no important changes in","ncit:positive","ncit:quantitative","The extent of increase depends on the formulation of verapamil and timing of administration. If verapamil is present in the gut when dabigatran is taken, it will increase exposure to dabigatran with the greatest increase observed when a single dose of immediate-release verapamil is given one hour prior to dabigatran (AUC increased by a factor of 2.4). If verapamil is given 2 hours after dabigatran, the increase in AUC is negligible.","dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","verapamil","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","Increase","UNK","UNK","UNK","UNK","UNK","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 17:29:38 -0500","DDI-clinical-trial","evidence-challenges","in ‘Poor Metabolizers’ and Potential Interaction With Drugs That Inhibit and/or Are Metabolized by Cytochrome P450 Isozymes.   Fluoxetine – "," When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively","","ncit:negative","ncit:quantitative",,"fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","HO-NEF","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","200","BID","Oral","UNK","QD","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:45:41 -0700","drug-drug-interaction","evidence-supports","potentiated the cognitive and motor effects of alcohol in a clinical trial in subjects with selected psychotic disorders, and alcoholic beverages should be limited while taking quetiapine .  ","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.). and decreased by the prototype CYP3A4 inducers (e..g, phenytoin, carbamazepine, rifampin, avasimibe, St. John’s wort etc.).","","ncit:positive","ncit:Qualitative","quetiapine exposure is decreased by CYP3A4 inducers","carbamazepine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"Quetiapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 18:52:09 -0700","DDI-clinical-trial","evidence-challenges","did not affect the pharmacokinetics of ziprasidone .     ","Ziprasidone at a dose of 40 mg twice daily administered concomitantly with lithium at a dose of 450 mg twice daily for 7 days did not affect the steady-state level or renal clearance of lithium. Ziprasidone dosed adjunctively to lithium in a maintenance trial of bipolar patients did not affect mean therapeutic lithium levels.","","ncit:negative","ncit:quantitative",,"Ziprasidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","lithium","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","450","BID","Oral","7","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 15:22:19 -0500","drug-drug-interaction","evidence-supports","    Immunosuppressive Agents   ","There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. Both cyclosporine and tacrolimus are substrates of CYP3A4, and nefazodone is known to inhibit this enzyme. If either cyclosporine or tacrolimus is administered with nefazodone, blood concentrations of the immunosuppressive agent should be monitored and dosage adjusted accordingly.","","ncit:positive","ncit:Qualitative","eports of increased blood concentrations","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"tacrolimus","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/fdbfe194-b845-42c5-bb87-a48118bc72e7.html","2016-03-31 12:22:57 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  ","Elevated plasma levels of HMG-CoA reductase inhibitory activity increases the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).] Concomitant use of drugs labeled as having a strong inhibitory effect on CYP3A4 is contraindicated [see Contraindications (4)]. If treatment with itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin must be suspended during the course of treatment.","","ncit:positive","ncit:Qualitative","strong inhibitor of CYP3A4 may elevate simvastatin plasma level","simvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","voriconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:34:30 -0700","drug-drug-interaction","evidence-supports","","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.)",". and decreased by the prototype CYP3A4 inducers (e..g,","ncit:positive","ncit:Qualitative","quetiapine exposure is increased by CYP3A4 inhibitors","itraconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"Quetiapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:45:41 -0700","drug-drug-interaction","evidence-supports","potentiated the cognitive and motor effects of alcohol in a clinical trial in subjects with selected psychotic disorders, and alcoholic beverages should be limited while taking quetiapine .  ","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.). and decreased by the prototype CYP3A4 inducers (e..g, phenytoin, carbamazepine, rifampin, avasimibe, St. John’s wort etc.).","","ncit:positive","ncit:Qualitative","quetiapine exposure is decreased by CYP3A4 inducers","Quetiapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","avasimibe","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c6e131fe-e7df-4876-83f7-9156fc4e8228.html","2016-03-14 15:11:38 -0700","drug-drug-interaction","evidence-supports","   7.9 Oral Contraceptives  ","Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)]. These increases should be considered when selecting an oral contraceptive for a woman taking LIPITOR","","ncit:positive","ncit:Qualitative","Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol","LIPITOR","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"ethinyl estradiol","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:43:26 -0700","drug-drug-interaction","evidence-supports","CYP2D6 and CYP3A4 Inhibitors   ","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)]","","ncit:positive","ncit:Qualitative","Sertraline can increase clozapine levels","sertraline","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 17:36:33 -0700","drug-drug-interaction","evidence-challenges","."," In a single-dose drug interaction study there were no pharmacokinetic or pharmacodynamic interactions observed after concomitant administration of naproxen or aspirin (acetylsalicylic acid) with XARELTO.","","ncit:negative","ncit:Qualitative","no pharmacokinetic or pharmacodynamic interactions observed after concomitant administration of naproxen or aspirin (acetylsalicylic acid) with XARELTO.","XARELTO","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","aspirin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:41:56 -0700","drug-drug-interaction","evidence-supports","CYP2D6 and CYP3A4 Inhibitors   ","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)]","","ncit:positive","ncit:Qualitative","Fluoxetine can increase clozapine levels","clozapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:50:39 -0700","drug-drug-interaction","evidence-supports","","Coadministration of ketoconazole, a potent inhibitor of cytochrome CYP3A4, resulted in significant increase in quetiapine exposure."," The dose of","ncit:positive","ncit:Qualitative","significantly increased quetiapine exposure","quetiapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 14:47:05 -0500","DDI-clinical-trial","evidence-challenges","are coadministered; plasma level monitoring for digoxin is recommended.  ","Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.","","ncit:negative","ncit:quantitative",,"propranolol","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","hydroxynefazodone","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","200","BID","Oral","5.5","BID","Oral","5.5","18","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 16:21:50 -0700","drug-drug-interaction","evidence-supports","","Results from drug interaction studies and population PK analyses from clinical studies indicate coadministration of XARELTO with a combined P-gp and strong CYP3A4 inducer (e.g., rifampicin, phenytoin) decreased rivaroxaban exposure by up to 50%."," Similar decreases in pharmacodynamic effects were also observed. These decreases in exposure to","ncit:positive","ncit:Qualitative","decreased rivaroxaban exposure by up to 50%.","rifampicin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/50914a46-eab6-4c83-97cf-6ab0234c8126.html","2017-03-15 14:57:45 -0400","drug-drug-interaction","evidence-supports","estazolam is catalyzed by CYP3A. ","While no in vivo drug-drug interaction studies were conducted between estazolam and inhibitors/inducers of CYP3A, compounds that are potent CYP3A inhibitors (such as ketoconazole, itraconazole, nefazodone, fluvoxamine, and erythromycin) would be expected to increase plasma estazolam concentrations and CYP3A inducers (such as carbamazepine, phenytoin, rifampin and barbiturates) would be expected to decrease estazolam concentrations. ","","ncit:positive","ncit:Qualitative",,"nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"estazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 17:33:34 -0500","DDI-clinical-trial","evidence-supports","in ‘Poor Metabolizers’ and Potential Interaction With Drugs That Inhibit and/or Are Metabolized by Cytochrome P450 Isozymes.   Fluoxetine – "," When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively","","ncit:positive","ncit:quantitative",,"mCPP","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","200","fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","BID","Oral","UNK","QD","Oral","UNK","UNK","3 to 6","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a971ea18-40cf-4a01-b696-180ccc3fddb5.html","2016-02-29 14:04:47 -0700","drug-drug-interaction","evidence-supports","Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly.  ","Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.","","ncit:positive","ncit:Qualitative","results in increased plasma levels of both drugs","propranolol","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"phenothiazines","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:31:54 -0400","DDI-clinical-trial","evidence-supports","dosage should be guided by usual clinical practices.  ","Desipramine – When nefazodone (150 mg BID) and desipramine (75 mg QD) were administered together there were no changes in the pharmacokinetics of desipramine or its metabolite, 2-hydroxy desipramine. There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.","","ncit:positive","ncit:quantitative",,"nefazodone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","150","desipramine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","75","BID","Oral","Unk","QD","Oral","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/aad8b373-0aec-4efb-8e61-3d8114b31127.html","2016-03-31 12:54:41 -0700","drug-drug-interaction","evidence-challenges","Pharmacokinetic data in the pediatric population are not available.   Drug-Drug Interactions:   ","Data from drug-drug interactions studies involving coadministration of gemfibrozil, niacin, itraconazole, erythromycin, tolbutamide or clopidogrel indicate that the PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with any of these drugs.","","ncit:negative","ncit:Qualitative","PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with gemfibrozil","gemfibrozil","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"fluvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2017-03-16 17:56:44 -0400","DDI-clinical-trial","evidence-supports","","Fluvoxamine, a CYP1A2 inhibitor, decreases the clearance of olanzapine. This results in a mean increase in olanzapine Cmax following fluvoxamine of 54% in female nonsmokers and 77% in male smokers. The mean increase in olanzapine AUC is 52% and 108%, respectively."," Lower doses of","ncit:positive","ncit:quantitative","range in AUC and Cmax changes for female nonsmokers and male smokers","olanzapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","fluvoxamine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","52-108","Percent","Increase","UNK","UNK","UNK","54-77","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:24:20 -0700","drug-drug-interaction","evidence-challenges",", but there was an additive effect of decreased alertness. ","Similarly, chlorpromazine in combination with zolpidem produced no pharmacokinetic interaction, but there was an additive effect of decreased alertness and psychomotor performance [see Clinical Pharmacology (12.3)].","","ncit:negative","ncit:Qualitative","produced no pharmacokinetic interaction,","zolpidem","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","chlorpromazine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/50914a46-eab6-4c83-97cf-6ab0234c8126.html","2017-03-15 15:03:45 -0400","drug-drug-interaction","evidence-supports","and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A. ","Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A (see CONTRAINDICATIONS). ","","ncit:positive","ncit:Qualitative",,"estazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","itraconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:36:22 -0700","DDI-clinical-trial","evidence-challenges","","No clinically relevant effect was observed on steady state lithium exposure following coadministration with multiple daily doses of BRINTELLIX."," Multiple doses of","ncit:negative","ncit:quantitative",,"lithium","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","BRINTELLIX","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a971ea18-40cf-4a01-b696-180ccc3fddb5.html","2016-02-29 16:08:19 -0500","drug-drug-interaction","evidence-supports","results in increased plasma levels of both drugs .  ","Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of Dilantin®‡ (phenytoin) and thus precipitate Dilantin (phenytoin) toxicity.","","ncit:positive","ncit:Qualitative","phenothiazines may precipitate Dilantin toxicity","Dilantin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","Phenothiazines","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e9481622-7cc6-418a-acb6-c5450daae9b0.html","2016-04-12 11:01:28 -0700","drug-drug-interaction","evidence-challenges","and Drug Interactions (7) ] .  ","In dedicated studies conducted in healthy subjects, famotidine, atenolol, prasugrel, and enoxaparin did not meaningfully alter the pharmacokinetics of apixaban.","","ncit:negative","ncit:Qualitative","enoxaparin did not meaningfully alter the pharmacokinetics of apixaban","enoxaparin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"apixaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 16:11:19 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. ","Strong inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, erythromycin, and cobicistat-containing products), and grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin. (See CONTRAINDICATIONS, WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics.)","","ncit:positive","ncit:Qualitative","posaconazole is a strong inhibitor of CYP3A4 and reduces the elimination of lovastatin","lovastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","posaconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 19:19:02 -0400","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. ","Strong inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, erythromycin, and cobicistat-containing products), and grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin. (See CONTRAINDICATIONS, WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics.)","","ncit:positive","ncit:Qualitative","Cobicistat is a strong inhibitor of CYP3A4 and reduces the elimination of lovastatin","lovastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","cobicistat","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 15:06:08 -0500","DDI-clinical-trial","evidence-supports","were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.  ","HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent","","ncit:positive","ncit:quantitative","entered plasma concentration as AUC","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","atorvastatin lactone","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","40","SD","Oral","1","BID","Oral","6","UNK","3 to 4","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:27:39 -0400","DDI-clinical-trial","evidence-challenges","or its metabolite, 2-hydroxy desipramine .  ","There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.","","ncit:negative","ncit:quantitative","DELETE","desipramine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","75","nefazodone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","150","BID","Oral","UNK","QD","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:44:17 -0700","DDI-clinical-trial","evidence-challenges","","Coadministration of aspirin 150 mg/day with multiple daily doses of BRINTELLIX had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin and salicylic acid [see Drug Interactions (7.4)]."," Patients receiving other drugs that interfere with hemostasis should be carefully monitored when","ncit:negative","ncit:quantitative",,"BRINTELLIX","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","aspirin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","150","Daily","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/50914a46-eab6-4c83-97cf-6ab0234c8126.html","2017-03-15 14:57:45 -0400","drug-drug-interaction","evidence-supports","estazolam is catalyzed by CYP3A. ","While no in vivo drug-drug interaction studies were conducted between estazolam and inhibitors/inducers of CYP3A, compounds that are potent CYP3A inhibitors (such as ketoconazole, itraconazole, nefazodone, fluvoxamine, and erythromycin) would be expected to increase plasma estazolam concentrations and CYP3A inducers (such as carbamazepine, phenytoin, rifampin and barbiturates) would be expected to decrease estazolam concentrations.","","ncit:positive","ncit:Qualitative",,"carbamazepine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"estazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5429f134-839f-4ffc-9944-55f51238def8.html","2015-12-18 15:57:58 -0500","DDI-clinical-trial","evidence-supports","on the pharmacokinetics of other co-administered drugs are summarized in Figure 2 .  ","Coadministration of paroxetine with SAPHRIS caused a two-fold increase in the maximum plasma concentrations and    systemic exposure of paroxetine. Asenapine enhances the inhibitory effects of paroxetine on its own metabolism by CYP2D6.","","ncit:positive","ncit:quantitative",,"paroxetine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","SAPHRIS","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","2","Fold","Increase","UNK","UNK","UNK","2","Fold","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:26:13 -0400","DDI-clinical-trial","evidence-challenges","or its metabolite, 2-hydroxy desipramine .  ","There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.","","ncit:negative","ncit:quantitative","DELETE","triazole-dione","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","150","desipramine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","75","BID","Oral","UNK","QD","Oral","UNK","UNK","UNK","UNK","UNK","UNKUNUNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 15:35:32 -0700","DDI-clinical-trial","evidence-supports","trough levels were observed in patients who received amiodarone .   ","Quinidine: Quinidine was given as a 200 mg dose every 2 hours up to a total dose of 1000 mg. Dabigatran etexilate was given over 3 consecutive days, the last evening dose on Day 3 with or without quinidine pre-dosing. Concomitant quinidine administration increased dabigatran’s AUC and Cmax by 53% and 56%, respectively.","","ncit:positive","ncit:quantitative","Note: quinidine regimen marked as unknown since Q2H up to 1000mg","quinidine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","up to 1000","dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","3","UNK","Oral","UNK","UNK","53","Percent","Increase","UNKUNUNK","UNK","UNK","56","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 16:46:00 -0500","DDI-clinical-trial","evidence-supports","","Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. ","When","ncit:positive","ncit:quantitative",,"fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","P88","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","3","SD","Oral","1","BID","Oral","21","23","2 to 3","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:43:01 -0700","drug-drug-interaction","evidence-supports","CYP2D6 and CYP3A4 Inhibitors   ","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)]","","ncit:positive","ncit:Qualitative","Terbinafine can increase clozapine levels","clozapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","terbinafine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:47:38 -0400","drug-drug-interaction","evidence-supports","7.1 Potential for Other Drugs to Affect LATUDA   ","LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)]. ","","ncit:positive","ncit:Qualitative",,"LATUDA","dikbD2R:drug-product","dikbD2R:object-drug-of-interaction",,"phenytoin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 16:08:43 -0700","drug-drug-interaction","evidence-challenges","Impact of Dabigatran on Other Drugs  ","In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine.","","ncit:negative","ncit:Qualitative","dabigatran did not meaningfully alter the pharmacokinetics of ranitidine","ranitidine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","dabigatran","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 18:07:55 -0700","DDI-clinical-trial","evidence-challenges"," is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known."," There is no pharmacokinetic interaction between zaleplon and diphenhydramine following the administration of a single dose (10 mg and 50 mg, respectively) of each drug. However, because both of these compounds have CNS effects, an additive pharmacodynamic effect is possible.","","ncit:negative","ncit:quantitative","no pharmacokinetic interaction between zaleplon and diphenhydramine","diphenhydramine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","50","zaleplon","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","10","SD","Oral","1","SD","Oral","1","UNK","UNK","UNK","UNK","UNKUNUNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/aad8b373-0aec-4efb-8e61-3d8114b31127.html","2016-03-30 15:07:23 -0700","drug-drug-interaction","evidence-supports","   7.2 Fluconazole  ","Administration of fluvastatin 40 mg single dose to healthy volunteers pre-treated with fluconazole for 4 days results in an increase of fluvastatin exposure. Therefore, in patients taking fluconazole, therapy should be limited to fluvastatin 20 mg twice daily [see Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","Concomitant fluconazole increases fluvastatin exposure. Details in Section 12 Table 3","fluconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"fluvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 16:27:07 -0700","drug-drug-interaction","evidence-supports","7.1 Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems  ","In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. The increases in exposure ranged from 30% to 160%. Significant increases in rivaroxaban exposure may increase bleeding risk [see Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","increases in rivaroxaban exposure","fluconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d78e9639-6fab-4a78-8b29-6991a18ae6c6.html","2016-02-19 17:46:51 -0500","drug-drug-interaction","evidence-supports","ity of this enzyme, so-called “poor” metabolizers. Among other populations the prevalence is not known. Poor metabolizers demonstrate higher plasma concentrations of antipsychotic drugs at usual doses, which may correlate with emergence of side effects. ","In one study of 45 elderly patients suffering from dementia treated with perphenazine, the 5 patients who were prospectively identified as poor P450 2D6 metabolizers had reported significantly greater side effects during the first 10 days of treatment than the 40 extensive metabolizers, following which the groups tended to converge. Prospective phenotyping of elderly patients prior to antipsychotic treatment may identify those at risk for adverse events.    The concomitant administration of other drugs that inhibit the activity of P450 2D6 may acutely increase plasma concentrations of antipsychotics. Among these are tricyclic antidepressants and selective serotonin reuptake inhibitors, e.g., fluoxetine, sertraline and paroxetine. When prescribing these drugs to patients already receiving antipsychotic therapy, close monitoring is essential and dose reduction may become necessary to avoid toxicity. Lower doses than usually prescribed for either the antipsychotic or the other drug may be required.","","ncit:positive","ncit:Qualitative","may acutely increase plasma concentrations of antipsychotics.","sertraline","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"perphenazine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/aad8b373-0aec-4efb-8e61-3d8114b31127.html","2016-03-30 15:11:14 -0700","drug-drug-interaction","evidence-supports","   7.8 Warfarin  ","Bleeding and/or increased prothrombin times have been reported in patients taking coumarin anticoagulants concomitantly with other HMG-CoA reductase inhibitors. Therefore, patients receiving warfarin-type anticoagulants should have their prothrombin times closely monitored when fluvastatin sodium is initiated or the dosage of fluvastatin sodium is changed.","","ncit:positive","ncit:Qualitative","Concomitant fluvastatin and warfarin have been reported to increase prothrombin time","warfarin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","fluvastatin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/fdbfe194-b845-42c5-bb87-a48118bc72e7.html","2016-03-31 12:38:39 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  ","Elevated plasma levels of HMG-CoA reductase inhibitory activity increases the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).] Concomitant use of drugs labeled as having a strong inhibitory effect on CYP3A4 is contraindicated [see Contraindications (4)]. If treatment with itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin must be suspended during the course of treatment.","","ncit:positive","ncit:Qualitative","strong inhibitor of CYP3A4 may elevate simvastatin plasma level","simvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","clarithromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html","2015-11-29 16:36:20 -0700","DDI-clinical-trial","evidence-challenges","is not recommended.   Valproate   ","Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (n=21). However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone. Dose adjustment for valproate is not recommended.","","ncit:negative","ncit:quantitative",,"valproate","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","1000","risperidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","4","Daily","Oral","UNK","QD","Oral","UNK","21","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1fd0ba23-962e-427f-8b9d-2cf8f64d0f95.html","2016-03-31 11:20:38 -0700","drug-drug-interaction","evidence-supports","  7.4 Coumarin Anticoagulants  ","CRESTOR significantly increased INR in patients receiving coumarin anticoagulants. Therefore, caution should be exercised when coumarin anticoagulants are given in conjunction with CRESTOR. In patients taking coumarin anticoagulants and CRESTOR concomitantly, INR should be determined before starting CRESTOR and frequently enough during early therapy to ensure that no significant alteration of INR occurs [seeWarnings and Precautions (5.3) and Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","CRESTOR significantly increased INR in patients receiving coumarin anticoagulants. Study details in Section 12 Table 5","CRESTOR","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"coumarin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 15:29:51 -0700","DDI-clinical-trial","evidence-supports",". Similar findings were observed in the RE-COVER study.   ","Amiodarone: When dabigatran etexilate was coadministered with a single 600 mg oral dose of amiodarone, the dabigatran AUC and Cmax increased by 58% and 50%, respectively. The increase in exposure was mitigated by a 65% increase in the renal clearance of dabigatran in the presence of amiodarone. The increase in renal clearance may persist after amiodarone is discontinued because of amiodarone’s long half-life. In the population pharmacokinetics study from RE-LY, no important changes in dabigatran trough levels were observed in patients who received amiodarone.","","ncit:positive","ncit:quantitative",,"dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","amiodarone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","600","UNK","Oral","UNK","SD","Oral","1","UNK","58","Percent","Increase","65","Percent","Increase","50","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e9481622-7cc6-418a-acb6-c5450daae9b0.html","2016-04-12 11:01:28 -0700","drug-drug-interaction","evidence-challenges","and Drug Interactions (7) ] .  ","In dedicated studies conducted in healthy subjects, famotidine, atenolol, prasugrel, and enoxaparin did not meaningfully alter the pharmacokinetics of apixaban.","","ncit:negative","ncit:Qualitative","famotidine did not meaningfully alter the pharmacokinetics of apixaban","apixaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","famotidine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 16:06:42 -0700","drug-drug-interaction","evidence-supports"," is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. ","Strong inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, erythromycin, and cobicistat-containing products), and grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin. (See CONTRAINDICATIONS, WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics.)","","ncit:positive","ncit:Qualitative","itraconazole is a strong inhibitor of cyP3A4 and reduces elimination of lovastatin","itraconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"lovastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a0da0dba-a56d-486b-a45b-e8a7cdfbeac6.html","2016-05-10 10:32:01 -0700","DDI-clinical-trial","evidence-supports","  Cimetidine  ","Coadministration of cimetidine increased the maximum plasma concentration of triazolam by 51%, decreased clearance by 55%, and increased half-life by 68%; caution and consideration of appropriate triazolam dose reduction are recommended.","","ncit:positive","ncit:quantitative",,"cimetidine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","triazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","55","Percent","Decrease","51","Percent","Increase","68","Percent","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:54:42 -0700","drug-drug-interaction","evidence-challenges","","Zolpidem tartrate had no effect on digoxin pharmacokinetics"," and did not affect","ncit:negative","ncit:Qualitative","had no effect on digoxin pharmacokinetics","digoxin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","Zolpidem","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 16:00:33 -0700","drug-drug-interaction","evidence-challenges","or the coagulation measures aPTT, ECT, or TT.   ","Diclofenac, Ranitidine, and Digoxin: None of these drugs alters exposure to dabigatran.","","ncit:negative","ncit:Qualitative","digoxin does not alter exposure to dabigatran.","Digoxin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 16:44:42 -0700","DDI-clinical-trial","evidence-supports","may be due to the relative difference in P-gp inhibition.   ","Erythromycin (combined P-gp and moderate CYP3A4 inhibitor): Both the single-dose rivaroxaban AUC and Cmax increased by 30%","","ncit:positive","ncit:quantitative",,"Erythromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","30","Percent","Increase","UNK","UNK","UNK","30","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 16:51:32 -0500","DDI-clinical-trial","evidence-supports","","Buspirone – In a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20 fold in Cmax and up to 50 fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine. ","With 5 mg BID doses of","ncit:positive","ncit:quantitative",,"nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","250","buspirone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","2.5 or 5","BID","Oral","UNK","BID","Oral","UNK","UNK","up to 50","Fold","Increase","UNK","UNK","UNK","up to 20","Fold","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 15:56:43 -0500","DDI-clinical-trial","evidence-supports","Interaction With Triazolobenzodiazepines  ","Interaction studies of nefazodone with two triazolobenzodiazepines, i.e., triazolam and alprazolam, metabolized by cytochrome P450 3A4, have revealed substantial and clinically important increases in plasma concentrations of these compounds when administered concomitantly with nefazodone.","","ncit:positive","ncit:quantitative","increases in plasma concentrations","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","triazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:21:10 -0400","DDI-clinical-trial","evidence-supports","dosage should be guided by usual clinical practices.  ","Desipramine – When nefazodone (150 mg BID) and desipramine (75 mg QD) were administered together there were no changes in the pharmacokinetics of desipramine or its metabolite, 2-hydroxy desipramine. There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.","","ncit:positive","ncit:quantitative",,"desipramine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","75","HO-NEF","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","150","BID","Oral","Unk","QD","Oral","Unk","Unk","19","Percent","Decrease","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 15:05:05 -0500","drug-drug-interaction","evidence-supports","","The coadministration of triazolam and nefazodone causes a significant increase in the plasma level of triazolam (see WARNINGS and PRECAUTIONS), and a 75% reduction in the initial triazolam dosage is recommended if the two drugs are to be given together. ","Because not all commercially available dosage forms of triazolam permit a sufficient dosage reduction, the coadministration of","ncit:positive","ncit:Qualitative","increase in the plasma level of triazolam","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"triazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2016-02-18 18:45:32 -0500","DDI-clinical-trial","evidence-supports","dose could then be increased to the previous level.   ","Paroxetine: Co-administration of paroxetine (20 mg/day for 5 to 8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18 to 65 years resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. ","","ncit:positive","ncit:quantitative",,"P88","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","8 or 12","paroxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","BID","Oral","UNK","Daily","Oral","5 to 8","UNK","UNK","UNK","UNK","UNK","UNK","UNK","1.6","Fold","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:28:00 -0700","DDI-clinical-trial","evidence-challenges","   Haloperidol   ","A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem. The lack of a drug interaction following single-dose administration does not predict the absence of an effect following chronic administration [see Clinical Pharmacology (12.3)].","","ncit:negative","ncit:quantitative","no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem.","haloperidol","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","zolpidem","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","SD","Oral","1","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:31:54 -0400","DDI-clinical-trial","evidence-supports","dosage should be guided by usual clinical practices.  ","Desipramine – When nefazodone (150 mg BID) and desipramine (75 mg QD) were administered together there were no changes in the pharmacokinetics of desipramine or its metabolite, 2-hydroxy desipramine. There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.","","ncit:positive","ncit:quantitative",,"triazole-dione","dikbD2R:metabolite","dikbD2R:precipitant-drug-of-interaction","75","desipramine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","150","BID","Oral","Unk","QD","Oral","Unk","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:37:21 -0700","DDI-clinical-trial","evidence-supports","Warnings and Precautions (5.1) ].   ","Following five consecutive nightly doses at bedtime of oral zolpidem tartrate 10 mg in the presence of sertraline 50 mg (17 consecutive daily doses, at 7:00 am, in healthy female volunteers), zolpidem Cmax was significantly higher (43%) and Tmax was significantly decreased (-53%). Pharmacokinetics of sertraline and N-desmethylsertraline were unaffected by zolpidem.","","ncit:positive","ncit:quantitative","max was significantly decreased (-53%).","zolpidem","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","10","sertraline","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","50","QD","Oral","5","QD","Oral","17","UNK","UNK","UNK","UNK","UNK","UNK","UNK","43","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2017-03-16 18:02:50 -0400","DDI-clinical-trial","evidence-supports"," —"," Olanzapine did not influence the pharmacokinetics of diazepam or its active metabolite N-desmethyldiazepam."," However,","ncit:negative","ncit:quantitative",,"diazepam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","Olanzapine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:27:39 -0400","DDI-clinical-trial","evidence-challenges","are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.  ","Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.","","ncit:negative","ncit:quantitative",,"Lithium","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","500","nefazodone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","200","BID","Oral","5","BID","Oral","5","13","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 14:51:10 -0500","DDI-clinical-trial","evidence-supports","are coadministered; plasma level monitoring for digoxin is recommended.  ","Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.","","ncit:positive","ncit:quantitative",,"m-chlorophenylpiperazine","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","200","propranolol","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","BID","Oral","5.5","BID","Oral","5.5","18","28","Percent","Increase","UNK","UNK","UNK","23","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 18:59:13 -0700","DDI-clinical-trial","evidence-challenges","(0.03 mg) and levonorgestrel (0.15 mg).     ","Consistent with in vitro results, a study in normal healthy volunteers showed that ziprasidone did not alter the metabolism of dextromethorphan, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio.","","ncit:negative","ncit:quantitative",,"dextrorphan","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","ziprasidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 15:59:31 -0500","DDI-clinical-trial","evidence-challenges","), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2) .   ","Because vortioxetine is highly bound to plasma protein, coadministration of BRINTELLIX with another drug that is highly protein bound may increase free concentrations of the other drug. However, in a clinical study with coadministration of BRINTELLIX (10 mg/day) and warfarin (1 mg/day to 10 mg/day), a highly protein-bound drug, no significant change in INR was observed [see Drug Interactions (7.2)].","","ncit:negative","ncit:quantitative",,"warfarin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","1 to 10","BRINTELLIX","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","Daily","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 15:55:48 -0700","DDI-clinical-trial","evidence-supports","     Other Drugs    ","Clopidogrel: When dabigatran etexilate was given concomitantly with a loading dose of 300 mg or 600 mg clopidogrel, the dabigatran AUC and Cmax increased by approximately 30% and 40%, respectively. The concomitant administration of dabigatran etexilate and clopidogrel resulted in no further prolongation of capillary bleeding times compared to clopidogrel monotherapy. When comparing combined treatment and the respective mono-treatments, the coagulation measures for dabigatran’s effect (aPTT, ECT, and TT) remained unchanged, and inhibition of platelet aggregation (IPA), a measurement of clopidogrel’s effect, remained unchanged.","","ncit:positive","ncit:quantitative",,"clopidogrel","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","300 or 600","dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","SD","Oral","1","UNK","30","Percent","Increase","UNK","UNK","UNK","40","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-02-18 18:51:21 -0500","DDI-clinical-trial","evidence-supports","Drug-Drug Interaction Studies    Fluvoxamine    ","A pharmacokinetic study was conducted in 16 schizophrenic patients who received clozapine under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated about 3-fold compared to baseline steady-state concentrations","","ncit:positive","ncit:quantitative",,"clozapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","fluvoxamine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","14","16","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html","2017-03-16 18:05:56 -0400","DDI-clinical-trial","evidence-supports","","Co-administration of INVEGA® 6 mg once daily with carbamazepine, a strong inducer of both CYP3A4 and P-glycoprotein (P-gp), at 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state Cmax and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone. A minor decrease in the amount of drug excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration."," On initiation of","ncit:positive","ncit:quantitative",,"INVEGA","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","6","carbamazepine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","QD","Oral","UNK","BID","Oral","UNK","UNK","37","Percent","Decrease","35","Percent","Increase","37","Percent","Decrease","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/44dcbf97-99ec-427c-ba50-207e0069d6d2.html","2016-03-31 10:14:00 -0700","drug-drug-interaction","evidence-supports","   7.1 Cyclosporine   ","Cyclosporine significantly increased pitavastatin exposure. Co-administration of cyclosporine with LIVALO is contraindicated [see Contraindications (4) and Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","Cyclosporine significantly increased pitavastatin exposure. Study details in Section 12 Table 3","Cyclosporine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"pitavastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 13:40:46 -0500","DDI-clinical-trial","evidence-challenges","","Desipramine – When nefazodone (150 mg BID) and desipramine (75 mg QD) were administered together there were no changes in the pharmacokinetics of desipramine or its metabolite, 2-hydroxy desipramine. ","There were also no changes in the pharmacokinetics of","ncit:negative","ncit:quantitative",,"Desipramine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","75","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","150","QD","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 17:32:41 -0700","DDI-clinical-trial","evidence-challenges","."," In another study, single doses of warfarin (15 mg) and XARELTO (5 mg) resulted in an additive effect on factor Xa inhibition and PT. Warfarin did not affect the pharmacokinetics of rivaroxaban.","","ncit:negative","ncit:quantitative","Warfarin did not affect the pharmacokinetics of rivaroxaban","rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","5","warfarin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","15","SD","Oral","1","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a0da0dba-a56d-486b-a45b-e8a7cdfbeac6.html","2016-05-10 10:37:18 -0700","DDI-clinical-trial","evidence-supports","  Isoniazid  ","Coadministration of isoniazid increased the maximum plasma concentration of triazolam by 20%, decreased clearance by 42%, and increased half-life by 31%.","","ncit:positive","ncit:quantitative",,"isoniazid","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","triazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","42","Percent","Decrease","20","Percent","Increase","31","Percent","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 17:39:20 -0700","DDI-clinical-trial","evidence-challenges","did not affect the pharmacokinetics of ethanol .  ","Imipramine: Coadministration of single doses of Zaleplon 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration. The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug","","ncit:negative","ncit:quantitative","no alteration of the pharmacokinetics of either drug","Zaleplon","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","imipramine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","75","SD","Oral","1","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:38:00 -0700","DDI-clinical-trial","evidence-challenges","","Multiple doses of BRINTELLIX did not affect the pharmacokinetics or pharmacodynamics (composite cognitive score) of diazepam."," A clinical study has shown that","ncit:negative","ncit:quantitative",,"diazepam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","BRINTELLIX","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:31:54 -0400","DDI-clinical-trial","evidence-supports","dosage should be guided by usual clinical practices.  ","Desipramine – When nefazodone (150 mg BID) and desipramine (75 mg QD) were administered together there were no changes in the pharmacokinetics of desipramine or its metabolite, 2-hydroxy desipramine. There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.","","ncit:positive","ncit:quantitative",,"mCPP","dikbD2R:metabolite","dikbD2R:precipitant-drug-of-interaction","75","desipramine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","150","BID","Oral","Unk","QD","Oral","Unk","Unk","44","Percent","Increase","Unk","UNK","UNK","48","Percent","Increase","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/fdbfe194-b845-42c5-bb87-a48118bc72e7.html","2016-03-31 12:22:33 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  ","Elevated plasma levels of HMG-CoA reductase inhibitory activity increases the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).] Concomitant use of drugs labeled as having a strong inhibitory effect on CYP3A4 is contraindicated [see Contraindications (4)]. If treatment with itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin must be suspended during the course of treatment.","","ncit:positive","ncit:Qualitative","strong inhibitor of CYP3A4 may elevate simvastatin plasma level","posaconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"simvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 20:54:45 -0400","DDI-clinical-trial","evidence-challenges","Drugs that are Substrates of CYP3A4 and/or Drug Transport Systems   ","In addition, there were no significant pharmacokinetic interactions observed in studies comparing concomitant rivaroxaban 20 mg and 7.5 mg single dose of midazolam (substrate of CYP3A4), 0.375 mg once-daily dose of digoxin (substrate of P-gp), or 20 mg once daily dose of atorvastatin (substrate of CYP3A4 and P-gp) in healthy volunteers.","","ncit:negative","ncit:quantitative","no significant pharmacokinetic interactions observed","atorvastatin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","20","UNK","Oral","UNK","QD","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 16:03:19 -0500","DDI-clinical-trial","evidence-challenges","half-life and AUC increased 4 fold and peak concentrations increased 1.7 fold. ","Nefazodone plasma concentrations were unaffected by triazolam.","","ncit:negative","ncit:quantitative",,"triazolam","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",".25","Nefazodone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","200","BID","Oral","UNK","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 17:41:00 -0700","DDI-clinical-trial","evidence-challenges","   Clopidogrel   ","In two drug interaction studies where clopidogrel (300 mg loading dose followed by 75 mg daily maintenance dose) and XARELTO (15 mg single dose) were coadministered in healthy subjects, an increase in bleeding time to 45 minutes was observed in approximately 45% and 30% of subjects in these studies, respectively. The change in bleeding time was approximately twice the maximum increase seen with either drug alone. There was no change in the pharmacokinetics of either drug.","","ncit:negative","ncit:quantitative","There was no change in the pharmacokinetics of either drug.","XARELTO","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","15","clopidogrel","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","75","SD","Oral","1","QD","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 19:04:34 -0700","DDI-clinical-trial","evidence-challenges","in a maintenance trial of bipolar patients did not affect mean therapeutic valproate levels.     ","Population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam.         The absolute bioavailability of a 20 mg dose under fed conditions is approximately 60%. The absorption of ziprasidone is increased up to two-fold in the presence of food","","ncit:negative","ncit:quantitative",,"benztropine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","ziprasidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 14:05:41 -0500","DDI-clinical-trial","evidence-challenges","    Cimetidine   ","When nefazodone (200 mg BID) and cimetidine (300 mg QID) were coadministered for one week, no change in the steady-state pharmacokinetics of either nefazodone or cimetidine was observed compared to each dosed alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.","","ncit:negative","ncit:quantitative",,"cimetidine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","300","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","QID","Oral","7","BID","Oral","7","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html","2015-11-29 16:36:20 -0700","DDI-clinical-trial","evidence-challenges","Risperidone on other drugs    Lithium   ","Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (n=13). Dose adjustment for lithium is not recommended.","","ncit:negative","ncit:quantitative",,"lithium","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","risperidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","3","UNK","Oral","UNK","BID","Oral","UNK","13","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/44dcbf97-99ec-427c-ba50-207e0069d6d2.html","2016-03-31 10:15:25 -0700","drug-drug-interaction","evidence-supports","   7.2 Erythromycin   ","Erythromycin significantly increased pitavastatin exposure. In patients taking erythromycin, a dose of LIVALO 1 mg once daily should not be exceeded [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)]. ","","ncit:positive","ncit:Qualitative","rythromycin significantly increased pitavastatin exposure. Study details in Section 12 Table 3","pitavastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","erythromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2017-03-16 17:57:25 -0400","DDI-clinical-trial","evidence-supports","","Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance",". The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended. When using","ncit:positive","ncit:quantitative",,"Fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","60","olanzapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","QD","Oral","8","UNK","UNK","UNK","UNK","16","Percent","Decrease","16","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e9481622-7cc6-418a-acb6-c5450daae9b0.html","2016-04-12 10:49:34 -0700","drug-drug-interaction","evidence-supports","7.2 Strong Dual Inducers of CYP3A4 and P-gp  ","Avoid concomitant use of ELIQUIS with strong dual inducers of CYP3A4 and P-gp (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban [see Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","carbamezepine will decrease exposure to apixaban","carbamazepine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"apixaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 17:43:16 -0700","DDI-clinical-trial","evidence-challenges","   Clopidogrel   ","In two drug interaction studies where clopidogrel (300 mg loading dose followed by 75 mg daily maintenance dose) and XARELTO (15 mg single dose) were coadministered in healthy subjects, an increase in bleeding time to 45 minutes was observed in approximately 45% and 30% of subjects in these studies, respectively. The change in bleeding time was approximately twice the maximum increase seen with either drug alone. There was no change in the pharmacokinetics of either drug.","","ncit:negative","ncit:quantitative","There was no change in the pharmacokinetics of either drug.","clopidogrel","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","15","XARELTO","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","75","SD","UNK","1","QD","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:40:58 -0400","DDI-clinical-trial","evidence-supports","and alcohol in depressed patients is not advised.  ","Buspirone – In a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20 fold in Cmax and up to 50 fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine.","","ncit:positive","ncit:quantitative",,"1-pyrimidinylpiperazine.","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","2.5 or 5","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","250","BID","Oral","UNK","BID","Oral","UNK","UNK","50","Percent","Decrease","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/39a5dae2-49f7-4662-9eac-aa7b4c7807a4.html","2016-05-09 19:28:30 -0400","DDI-clinical-trial","evidence-supports",", but a pharmacodynamic interaction was seen on a measure of psychomotor function.  ","Eszopiclone and lorazepam decreased each other's Cmax by 22%. ","","ncit:positive","ncit:quantitative",,"lorazepam","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","Eszopiclone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","22","Percent","Decrease","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1fd0ba23-962e-427f-8b9d-2cf8f64d0f95.html","2016-03-31 11:07:53 -0700","DDI-clinical-trial","evidence-supports","   7.1 Cyclosporine  ","Cyclosporine increased rosuvastatin exposure (AUC) 7‑fold. Therefore, in patients taking cyclosporine, the dose of CRESTOR should not exceed 5 mg once daily [seeDosage and Administration (2.5), Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)].","","ncit:positive","ncit:quantitative","Study details in section 12 Table 4","cyclosporine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","rosuvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","7","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-12 13:35:35 -0400","drug-drug-interaction","evidence-challenges",".","    Diclofenac, Ranitidine, and Digoxin: None of these drugs alters exposure to dabigatran.","","ncit:negative","ncit:Qualitative","diclofenac does not alter exposure to dabigatran","dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","Diclofenac","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 17:24:30 -0500","DDI-clinical-trial","evidence-challenges"," –"," When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine."," Similarly, there were no changes in the pharmacokinetic parameters of","ncit:negative","ncit:quantitative",,"fluoxetine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","20","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","QD","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 16:26:31 -0700","drug-drug-interaction","evidence-supports","7.1 Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems  ","In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. The increases in exposure ranged from 30% to 160%. Significant increases in rivaroxaban exposure may increase bleeding risk [see Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","increases in rivaroxaban exposure","ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2017-03-16 17:58:23 -0400","drug-drug-interaction","evidence-supports"," — ","Single doses of olanzapine did not affect the pharmacokinetics of warfarin ","","ncit:negative","ncit:Qualitative",,"olanzapine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"warfarin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:20:40 -0700","drug-drug-interaction","evidence-supports","Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias.  ","Reduced cytochrome P450 2D6 isozyme activity drugs that inhibit this isozyme (e.g., fluoxetine and paroxetine) and certain other drugs (e.g., fluvoxamine, propranolol, and pindolol) appear to appreciably inhibit the metabolism of thioridazine. The resulting elevated levels of thioridazine would be expected to augment the prolongation of the QTc interval associated with thioridazine and may increase the risk of serious, potentially fatal, cardiac arrhythmias, such as Torsades de pointes type arrhythmias.","","ncit:positive","ncit:Qualitative","appear to appreciably inhibit the metabolism of thioridazine and result in elevated levels of thioridazine","thioridazine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","fluvoxamine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:47:38 -0400","drug-drug-interaction","evidence-supports","7.1 Potential for Other Drugs to Affect LATUDA   ","LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)]. ","","ncit:positive","ncit:Qualitative",,"mibefradil","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","","LATUDA","dikbD2R:drug-product","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:38:01 -0700","drug-drug-interaction","evidence-supports","concomitantly with drugs that are inducers or inhibitors of these enzymes.   CYP1A2 Inhibitors   ","Concomitant use of CLOZARIL and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the CLOZARIL dose to one-third of the original dose when CLOZARIL is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The CLOZARIL dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued [see Dosage and Administration (2.6), Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","enoxacin can increase clozapine levels","enoxacin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:52:49 -0700","DDI-clinical-trial","evidence-challenges"," is unlikely to induce the metabolism of drugs metabolized by these CYP isoforms. ","Furthermore, in a series of clinical drug interaction studies, coadministration of BRINTELLIX with substrates for CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2).","","ncit:negative","ncit:quantitative",,"bupropion","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","BRINTELLIX","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/50914a46-eab6-4c83-97cf-6ab0234c8126.html","2017-03-15 14:52:59 -0400","drug-drug-interaction","evidence-supports","estazolam is catalyzed by CYP3A. ","While no in vivo drug-drug interaction studies were conducted between estazolam and inhibitors/inducers of CYP3A, compounds that are potent CYP3A inhibitors (such as ketoconazole, itraconazole, nefazodone, fluvoxamine, and erythromycin) would be expected to increase plasma estazolam concentrations and CYP3A inducers (such as carbamazepine, phenytoin, rifampin and barbiturates) would be expected to decrease estazolam concentrations. ","","ncit:positive","ncit:Qualitative",,"estazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","itraconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:36:49 -0700","drug-drug-interaction","evidence-supports","C","oncomitant use of CLOZARIL and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the CLOZARIL dose to one-third of the original dose when CLOZARIL is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The CLOZARIL dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued [see Dosage and Administration (2.6), Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","Fluvoxamine can increase clozapine levels","clozapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","fluvoxamine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 17:35:47 -0700","DDI-clinical-trial","evidence-challenges",", reflecting the absence of a role of CYP2D6 in zaleplon 's metabolism.  ","Thioridazine: Coadministration of single doses of Zaleplon 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration. The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug.","","ncit:negative","ncit:quantitative","no alteration of the pharmacokinetics of either drug.","thioridazine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","50","Zaleplon","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","20","SD","Oral","1","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 15:21:53 -0700","DDI-clinical-trial","evidence-supports","is administered 2 hours after dabigatran etexilate .   ","Ketoconazole: Systemic ketoconazole increased dabigatran AUC and Cmax values by 138% and 135%, respectively, after a single dose of 400 mg, and 153%, and 149%, respectively, after multiple daily doses of 400 mg.","","ncit:positive","ncit:quantitative","This is multiple ketoconazole doses","ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","400","dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","QD","Oral","UNK","UNK","153","Percent","Increase","UNK","UNK","UNK","149","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 16:33:28 -0500","DDI-clinical-trial","evidence-challenges","may be necessary when coadministered with nefazodone .  ","Lorazepam – When lorazepam (2 mg BID) and nefazodone (200 mg BID) were coadministered to steady state, there was no change in any pharmacokinetic parameter for either drug compared to each drug administered alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.","","ncit:negative","ncit:quantitative",,"Lorazepam","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","2","nefazodone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","200","BID","Oral","UNK","BID","Oral","UNK","UNK","UNKUNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 15:57:08 -0700","drug-drug-interaction","evidence-challenges","lovastatin and propranolol .   ","Digoxin: In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations","","ncit:negative","ncit:Qualitative","concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations","lovastatin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"digoxin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 19:05:25 -0700","DDI-clinical-trial","evidence-challenges","in a maintenance trial of bipolar patients did not affect mean therapeutic valproate levels.     ","Population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam.         The absolute bioavailability of a 20 mg dose under fed conditions is approximately 60%. The absorption of ziprasidone is increased up to two-fold in the presence of food","","ncit:negative","ncit:quantitative",,"ziprasidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","lorazepam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 16:55:02 -0500","DDI-clinical-trial","evidence-supports","dose could then be increased to the previous level.   ","Paroxetine: Co-administration of paroxetine (20 mg/day for 5 to 8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18 to 65 years resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. ","","ncit:positive","ncit:quantitative",,"paroxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","P95","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","8 or 12","BID","Oral","UNK","Daily","Oral","5 to 8","UNK","UNK","UNK","UNK","UNK","UNK","UNK","50","Percent","Decrease","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:17:25 -0400","DDI-clinical-trial","evidence-supports","","With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%)."," Subjects receiving","ncit:positive","ncit:quantitative","DELETE","buspirone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","5","nefazodone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","250","BID","Oral","UNK","BID","Oral","UNK","UNK","23","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 16:46:00 -0500","DDI-clinical-trial","evidence-supports","","Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. ","When","ncit:positive","ncit:quantitative",,"iloperidone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","3","fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","SD","Oral","1","BID","Oral","21","23","2 to 3","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1fd0ba23-962e-427f-8b9d-2cf8f64d0f95.html","2016-03-31 14:25:54 -0400","drug-drug-interaction","evidence-challenges","   7.6 Fenofibrate  ","When CRESTOR was coadministered with fenofibrate, no clinically significant increase in the AUC of rosuvastatin or fenofibrate was observed. Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concomitant use of fenofibrates, caution should be used when prescribing fenofibrates with CRESTOR [seeWarnings and Precautions (5.1) andClinical Pharmacology (12.3)]","","ncit:negative","ncit:Qualitative","When CRESTOR was coadministered with fenofibrate, no clinically significant increase in the AUC of rosuvastatin or fenofibrate was observed.","rosuvastatin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"fenofibrate","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 15:54:45 -0700","drug-drug-interaction","evidence-challenges","","Coumarin Anticoagulants: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected. However, another HMG‑CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin. Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin. ","It is recommended that in patients taking anticoagulants,","ncit:negative","ncit:Qualitative","Concomitant lovastatin and warfarin did not effect prothrombin time. But bleeding and increased prothrombin time have been reported with lovastatin and warfarin.","warfarin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","lovastatin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 16:47:42 -0700","DDI-clinical-trial","evidence-supports","AUC and C max increased by 30% .   ","Fluconazole (moderate CYP3A4 inhibitor): Single-dose rivaroxaban AUC and Cmax increased by 40% and 30%, respectively.","","ncit:positive","ncit:quantitative",,"rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","Fluconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","40","Percent","Increase","UNK","UNK","UNK","30","Percent","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 14:34:19 -0500","drug-drug-interaction","evidence-challenges"," — ","Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine. ","","ncit:negative","ncit:Qualitative","did not affect the oral bioavailability","cimetidine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"olanzapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 16:04:29 -0700","drug-drug-interaction","evidence-challenges","Impact of Dabigatran on Other Drugs  ","In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine.","","ncit:negative","ncit:Qualitative","dabigatran did not meaningfully alter the pharmacokinetics of amiodarone","amiodarone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","dabigatran","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 18:57:43 -0500","DDI-clinical-trial","evidence-supports","","Coadministration of quetiapine and phenytoin, a CYP3A4 inducer increased the mean oral clearance of quetiapine by 5-fold."," Increased doses of","ncit:positive","ncit:quantitative",,"quetiapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","phenytoin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","5","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:57:37 -0700","DDI-clinical-trial","evidence-challenges","is unlikely to induce the metabolism of drugs metabolized by these CYP isoforms. ","Furthermore, in a series of clinical drug interaction studies, coadministration of BRINTELLIX with substrates for CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2).","","ncit:negative","ncit:quantitative",,"BRINTELLIX","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","warfarin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:57:37 -0700","DDI-clinical-trial","evidence-challenges","is unlikely to induce the metabolism of drugs metabolized by these CYP isoforms. ","Furthermore, in a series of clinical drug interaction studies, coadministration of BRINTELLIX with substrates for CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2)","","ncit:negative","ncit:quantitative",,"diazepam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","BRINTELLIX","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e9481622-7cc6-418a-acb6-c5450daae9b0.html","2016-04-12 14:04:43 -0400","drug-drug-interaction","evidence-challenges","did not meaningfully alter the pharmacokinetics of apixaban .  ","In studies conducted in healthy subjects, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, atenolol, prasugrel, or acetylsalicylic acid.","","ncit:negative","ncit:Qualitative","pixaban did not meaningfully alter the pharmacokinetics of prasugrel","apixaban","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"prasugrel","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:40:02 -0700","drug-drug-interaction","evidence-supports","  Propranolol  ","Concurrent administration of propranolol (100 to 800 mg daily) has been reported to produce increases in plasma levels of thioridazine (approximately 50% to 400%) and its metabolites (approximately 80% to 300%). Propranolol and thioridazine should not be coadministered.","","ncit:positive","ncit:Qualitative","increases in plasma levels of thioridazine (approximately 50% to 400%) and its metabolites (approximately 80% to 300%)","thioridazine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","Propranolol","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 14:55:51 -0700","DDI-clinical-trial","evidence-supports","Impact of Other Drugs on Dabigatran   P-gp Inducers    ","Rifampin: Rifampin 600 mg once daily for 7 days followed by a single dose of dabigatran decreased its AUC and Cmax by 66% and 67%, respectively. By Day 7 after cessation of rifampin treatment, dabigatran exposure was close to normal [see Warnings and Precautions (5.5) and Drug Interactions (7)].","","ncit:positive","ncit:quantitative",,"dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","rifampin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","600","SD","Oral","1","QD","Oral","7","UNK","66","Percent","Decrease","UNK","UNK","UNK","67","Percent","Decrease","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:45:41 -0700","drug-drug-interaction","evidence-supports","","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.). and decreased by the prototype CYP3A4 inducers (e..g, phenytoin, carbamazepine, rifampin, avasimibe, St. John’s wort etc.)."," Dose adjustment of","ncit:positive","ncit:Qualitative","quetiapine exposure is decreased by CYP3A4 inducers","phenytoin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"Quetiapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:10:03 -0400","drug-drug-interaction","evidence-challenges","are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.  ","Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.","","ncit:negative","ncit:Qualitative",,"Lithium","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"HO-NEF","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 17:27:03 -0500","DDI-clinical-trial","evidence-challenges","","When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively."," When a 200 mg dose of","ncit:negative","ncit:quantitative",,"nefazodone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","200","fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","BID","Oral","UNK","QD","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 15:04:34 -0500","DDI-clinical-trial","evidence-supports","were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.  ","HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent","","ncit:positive","ncit:quantitative","entered plasma concentration as AUC","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","atorvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","40","SD","Oral","1","BID","Oral","6","UNK","3 to 4","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 14:11:14 -0500","DDI-clinical-trial","evidence-challenges","    Theophylline   ","When nefazodone (200 mg BID) was given to patients being treated with theophylline (600 to 1200 mg/day) for chronic obstructive pulmonary disease, there was no change in the steady-state pharmacokinetics of either nefazodone or theophylline. FEV1 measurements taken when theophylline and nefazodone were coadministered did not differ from baseline dosage (i.e., when theophylline was administered alone). Therefore, dosage adjustment is not necessary for either drug when coadministered.","","ncit:negative","ncit:quantitative",,"nefazodone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","200","theophylline","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","600 to 1200","BID","Oral","UNK","Daily","Oral","UNK","UNK","UNK","UNK","UNK","UNKUNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 15:02:14 -0700","DDI-clinical-trial","evidence-supports","and AUC are described below.   ","Dronedarone: Simultaneous administration of dabigatran etexilate and dronedarone (administered once or twice daily) increases exposure to dabigatran by 70 to 140% compared to dabigatran alone. The increase in exposure is only 30 to 60% higher compared to dabigatran alone when dronedarone is administered 2 hours after dabigatran etexilate","","ncit:positive","ncit:quantitative","The increase in exposure is only 30 to 60% higher compared to dabigatran alone when dronedarone is administered 2 hours after dabigatran etexilate","dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","dronedarone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","70-1470-140","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:40:35 -0700","DDI-clinical-trial","evidence-challenges","Warnings and Precautions (5.1) ].   ","Following five consecutive nightly doses at bedtime of oral zolpidem tartrate 10 mg in the presence of sertraline 50 mg (17 consecutive daily doses, at 7:00 am, in healthy female volunteers), zolpidem Cmax was significantly higher (43%) and Tmax was significantly decreased (-53%). Pharmacokinetics of sertraline and N-desmethylsertraline were unaffected by zolpidem.","","ncit:negative","ncit:quantitative","Pharmacokinetics of sertraline and N-desmethylsertraline were unaffected by zolpidem.","zolpidem","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","10","N-desmethylsertraline","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","50","QD","Oral","17","QD","Oral","5","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 14:37:36 -0500","DDI-clinical-trial","evidence-supports","","Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol."," The kinetics of","ncit:positive","ncit:quantitative",,"nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","propranolol","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","40","BID","Oral","5.5","BID","Oral","5.5","18","14","Percent","Decrease","UNK","UNK","UNK","30","Percent","Decrease","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:09:10 -0400","DDI-clinical-trial","evidence-supports","were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.  ","HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent","","ncit:positive","ncit:quantitative","entered plasma concentration as AUC","simvastatin acid","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","40","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","SD","Oral","1","BID","Oral","6","UNK","20","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:39:55 -0700","drug-drug-interaction","evidence-supports","CYP2D6 and CYP3A4 Inhibitors   ","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)].","","ncit:positive","ncit:Qualitative","Erythromycin can increase clozapine levels","erythromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:47:38 -0400","drug-drug-interaction","evidence-supports","7.1 Potential for Other Drugs to Affect LATUDA   ","LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)]. ","","ncit:positive","ncit:Qualitative",,"avasimibe","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","","LATUDA","dikbD2R:drug-product","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:43:01 -0700","drug-drug-interaction","evidence-supports","CYP2D6 and CYP3A4 Inhibitors   ","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)]","","ncit:positive","ncit:Qualitative","Duloxetine can increase clozapine levels","clozapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","duloxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/39a5dae2-49f7-4662-9eac-aa7b4c7807a4.html","2016-05-09 19:39:00 -0400","DDI-clinical-trial","evidence-challenges","","Digoxin: A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days. ","","ncit:negative","ncit:quantitative","digoxin dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days","digoxin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction",".25","eszopiclone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","3","Daily","Oral","6","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:30:14 -0700","DDI-clinical-trial","evidence-supports","   Fluoxetine   ","After multiple doses of zolpidem tartrate and fluoxetine an increase in the zolpidem half-life (17%) was observed. There was no evidence of an additive effect in psychomotor performance [see Clinical Pharmacology (12.3)].","","ncit:positive","ncit:quantitative",,"fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","zolpidem","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","17","Percent","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 17:07:38 -0500","DDI-clinical-trial","evidence-supports","metabolite 1-pyrimidinylpiperazine.  ","With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%)","","ncit:positive","ncit:quantitative",,"buspirone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","5","mCPP","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","250","BID","Oral","UNK","BID","Oral","UNK","UNK","9","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 15:52:59 -0700","DDI-clinical-trial","evidence-supports","; but ","when ticagrelor 180 mg was given 2 hours after dabigatran, the AUCτ,ss and Cmax,ss of dabigatran increased by only 27% and 24%, respectively [see Warnings and Precautions (5.2) and Drug Interactions (7.1)].","","ncit:positive","ncit:quantitative","ticagrlor given 2 hours after dabigatran resulted in less of AUC and CMAX increases than concomitant dosing","dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","ticagrelor","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","180","UNK","Oral","UNK","SD","Oral","1","UNK","27","Percent","Increase","UNK","UNK","UNK","24","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 16:51:56 -0700","DDI-clinical-trial","evidence-supports","Drugs that Induce Cytochrome P450 3A4 Enzymes and Drug Transport Systems   ","In a drug interaction study, coadministration of XARELTO (20 mg single dose with food) with a drug that is a combined P-gp and strong CYP3A4 inducer (rifampicin titrated up to 600 mg once daily) led to an approximate decrease of 50% and 22% in AUC and Cmax, respectively. Similar decreases in pharmacodynamic effects were also observed. These decreases in exposure to rivaroxaban may decrease efficacy.","","ncit:positive","ncit:quantitative",,"rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","20","rifampicin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","600","SD","Oral","1","QD","Oral","UNK","UNK","50","Percent","Decrease","UNK","UNK","UNK","22","Percent","Decrease","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 16:24:14 -0500","DDI-clinical-trial","evidence-supports","","Haloperidol – When a single oral 5 mg dose of haloperidol was coadministered with nefazodone (200 mg BID) at steady state, haloperidol apparent clearance decreased by 35% with no significant increase in peak haloperidol plasma concentrations or time of peak."," This change is of unknown clinical significance. Pharmacodynamic effects of","ncit:positive","ncit:quantitative",,"nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","haloperidol","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","5","SD","Oral","1","BID","Oral","UNK","UNK","UNK","UNK","UNK","35","Percent","Decrease","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:42:04 -0700","DDI-clinical-trial","evidence-challenges","","Following coadministration of stable doses of warfarin (1 to 10 mg/day) with multiple daily doses of BRINTELLIX, no significant effects were observed in INR, prothrombin values or total warfarin (protein bound plus free drug) pharmacokinetics for both R- and S-warfarin [see Drug Interactions (7.4)]."," Coadministration of","ncit:negative","ncit:quantitative",,"BRINTELLIX","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","warfarin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","1 to 10","Daily","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 18:57:19 -0700","DDI-clinical-trial","evidence-challenges","in a maintenance trial of bipolar patients did not affect mean therapeutic lithium levels.      ","In vivo studies have revealed no effect of ziprasidone on the pharmacokinetics of estrogen or progesterone components. Ziprasidone at a dose of 20 mg twice daily did not affect the pharmacokinetics of concomitantly administered oral contraceptives, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg).","","ncit:negative","ncit:quantitative",,"levonorgestrel","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction",".15","Ziprasidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","UNK","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 16:44:38 -0500","drug-drug-interaction","evidence-supports","  Pindolol  ","Concurrent administration of pindolol and thioridazine have resulted in moderate, dose related increases in the serum levels of thioridazine and two of its metabolites, as well as higher than expected serum pindolol levels. Pindolol and thioridazine should not be coadministered.","","ncit:positive","ncit:Qualitative","concomitant use with thirodazine produced higher than expected serum pindolol levels.","pindolol","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","thioridazine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e9481622-7cc6-418a-acb6-c5450daae9b0.html","2016-04-12 14:04:43 -0400","drug-drug-interaction","evidence-challenges","did not meaningfully alter the pharmacokinetics of apixaban .  ","In studies conducted in healthy subjects, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, atenolol, prasugrel, or acetylsalicylic acid.","","ncit:negative","ncit:Qualitative","pixaban did not meaningfully alter the pharmacokinetics of acetylsalicylic acid","acetylsalicylic acid","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","apixaban","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:39:55 -0700","drug-drug-interaction","evidence-supports","CYP2D6 and CYP3A4 Inhibitors   ","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)]. ","","ncit:positive","ncit:Qualitative","cimetidine can increase clozapine levels","cimetidine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5429f134-839f-4ffc-9944-55f51238def8.html","2015-12-18 13:50:52 -0700","DDI-clinical-trial","evidence-supports","CYP2D6 substrates and inhibitors (e.g., paroxetine )  ","SAPHRIS may enhance the inhibitory effects of paroxetine on its own metabolism. Concomitant use of paroxetine with SAPHRIS increased the paroxetine exposure by 2-fold as compared to use paroxetine alone [see Clinical Pharmacology (12.3)].","","ncit:positive","ncit:quantitative",,"SAPHRIS","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","paroxetine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","2","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html","2015-11-29 18:14:39 -0500","DDI-clinical-trial","evidence-challenges","","In a drug interaction study, co-administration of INVEGA® (12 mg once daily for 5 days) with divalproex sodium extended-release tablets (500 mg to 2000 mg once daily) did not affect the steady-state pharmacokinetics (AUC24h and Cmax,ss) of valproate in 13 patients stabilized on valproate. ","In a clinical study, subjects on stable doses of","ncit:negative","ncit:quantitative",,"INVEGA","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","12","divalproex sodium","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","500 to 2000","QD","Oral","UNK","QD","Oral","5","13","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 16:00:33 -0700","drug-drug-interaction","evidence-challenges","or the coagulation measures aPTT, ECT, or TT.   ","Diclofenac, Ranitidine, and Digoxin: None of these drugs alters exposure to dabigatran.","","ncit:negative","ncit:Qualitative","ranitidine does not alter exposure to dabigatran.","dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","Ranitidine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 17:30:22 -0700","DDI-clinical-trial","evidence-challenges","did not affect the pharmacokinetics of ethanol .  ","Imipramine: Coadministration of single doses of Zaleplon 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration. The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug.","","ncit:negative","ncit:quantitative","with no alteration of the pharmacokinetics of either drug.","imipramine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","75","Zaleplon","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","20","SD","Oral","1","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:41:56 -0700","drug-drug-interaction","evidence-supports","CYP2D6 and CYP3A4 Inhibitors   ","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)]","","ncit:positive","ncit:Qualitative","Bupropion can increase clozapine levels","bupropion","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/aad8b373-0aec-4efb-8e61-3d8114b31127.html","2016-03-31 12:57:26 -0700","drug-drug-interaction","evidence-challenges","Pharmacokinetic data in the pediatric population are not available.   Drug-Drug Interactions:   ","Data from drug-drug interactions studies involving coadministration of gemfibrozil, niacin, itraconazole, erythromycin, tolbutamide or clopidogrel indicate that the PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with any of these drugs.","","ncit:negative","ncit:Qualitative","PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with clopidogrel","clopidogrel","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"fluvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2017-03-16 18:02:50 -0400","DDI-clinical-trial","evidence-supports","","Olanzapine did not influence the pharmacokinetics of diazepam or its active metabolite N-desmethyldiazepam."," However,","ncit:negative","ncit:quantitative",,"N-desmethyldiazepam.","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","UNK","Olanzapine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:38:58 -0700","DDI-clinical-trial","evidence-challenges","Warnings and Precautions (5.1) ].   ","Following five consecutive nightly doses at bedtime of oral zolpidem tartrate 10 mg in the presence of sertraline 50 mg (17 consecutive daily doses, at 7:00 am, in healthy female volunteers), zolpidem Cmax was significantly higher (43%) and Tmax was significantly decreased (-53%). Pharmacokinetics of sertraline and N-desmethylsertraline were unaffected by zolpidem.","","ncit:negative","ncit:quantitative","Pharmacokinetics of sertraline and N-desmethylsertraline were unaffected by zolpidem.","zolpidem","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","10","sertraline","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","50","QD","Oral","1","QD","Oral","5","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/aad8b373-0aec-4efb-8e61-3d8114b31127.html","2016-03-30 15:08:21 -0700","drug-drug-interaction","evidence-supports","   7.6 Glyburide  ","Concomitant administration of fluvastatin and glyburide increased glyburide exposures. Patients on concomitant therapy of glyburide and fluvastatin should continue to be monitored appropriately [see Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","Concomitant fluvastatin increases glyburide exposure. Details in Section 12 Table 3","glyburide","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","fluvastatin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 18:44:10 -0700","DDI-clinical-trial","evidence-supports","and dopamine agonists.       Carbamazepine    ","Carbamazepine is an inducer of CYP3A4; administration of 200 mg twice daily for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone. This effect may be greater when higher doses of carbamazepine are administered. ","","ncit:positive","ncit:quantitative",,"carbamazepine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","ziprasidone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","BID","Oral","21","UNK","35","Percent","Decrease","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/39a5dae2-49f7-4662-9eac-aa7b4c7807a4.html","2017-03-15 15:12:42 -0400","drug-drug-interaction","evidence-supports","","Paroxetine: Coadministration of single dose of eszopiclone and paroxetine produced no pharmacokinetic or pharmacodynamic interaction. The lack of a drug interaction following single-dose administration does not predict the complete absence of a pharmacodynamic effect following chronic administration. ","","ncit:negative","ncit:Qualitative","Coadministration of single dose of eszopiclone and paroxetine produced no pharmacokinetic or pharmacodynamic interaction.","paroxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"eszopiclone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1fd0ba23-962e-427f-8b9d-2cf8f64d0f95.html","2016-03-31 11:20:38 -0700","drug-drug-interaction","evidence-supports","   7.2 Gemfibrozil  ","Gemfibrozil significantly increased rosuvastatin exposure. Due to an observed increased risk of myopathy/rhabdomyolysis, combination therapy with CRESTOR and gemfibrozil should be avoided. If used together, the dose of CRESTOR should not exceed 10 mg once daily [seeClinical Pharmacology (12.3)]","","ncit:positive","ncit:Qualitative","Gemfibrozil significantly increased rosuvastatin exposure. Study details in Section 12 Table 4","gemfibrozil","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"rosuvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e9481622-7cc6-418a-acb6-c5450daae9b0.html","2016-04-12 11:01:28 -0700","drug-drug-interaction","evidence-challenges","and Drug Interactions (7) ] .  ","In dedicated studies conducted in healthy subjects, famotidine, atenolol, prasugrel, and enoxaparin did not meaningfully alter the pharmacokinetics of apixaban.","","ncit:negative","ncit:Qualitative","prasugrel did not meaningfully alter the pharmacokinetics of apixaban","apixaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","prasugrel","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:47:38 -0400","drug-drug-interaction","evidence-supports","7.1 Potential for Other Drugs to Affect LATUDA   ","LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)]. ","","ncit:positive","ncit:Qualitative",,"LATUDA","dikbD2R:drug-product","dikbD2R:object-drug-of-interaction",,"ritonavir","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 19:19:02 -0400","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. ","Strong inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, erythromycin, and cobicistat-containing products), and grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin. (See CONTRAINDICATIONS, WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics.)","","ncit:positive","ncit:Qualitative","Erythromycin is a strong inhibitor of CYP3A4 and reduces the elimination of lovastatin","erythromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"lovastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 16:13:29 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. ","Strong inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, erythromycin, and cobicistat-containing products), and grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin. (See CONTRAINDICATIONS, WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics.)","","ncit:positive","ncit:Qualitative","voriconazole is a strong inhibitor of CYP3A4 and reduces the elimination of lovastatin","lovastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","voriconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 18:50:07 -0700","DDI-clinical-trial","evidence-challenges","by about 35–40%. Other inhibitors of CYP3A4 would be expected to have similar effects.       Cimetidine     ","Cimetidine at a dose of 800 mg QD for 2 days did not affect ziprasidone pharmacokinetics.","","ncit:negative","ncit:quantitative",,"ziprasidone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","Cimetidine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","800","UNK","Oral","UNK","QD","Oral","2","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2015-12-18 15:38:03 -0700","DDI-clinical-trial","evidence-supports","Drug-Drug Interaction Studies    Fluvoxamine    ","A pharmacokinetic study was conducted in 16 schizophrenic patients who received clozapine under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated about 3-fold compared to baseline steady-state concentrations.","","ncit:positive","ncit:quantitative",,"fluvoxamine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","N-desmethylclozapine","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","UNK","UNK","UNK","UNK","UNK","Oral","14","16","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/fdbfe194-b845-42c5-bb87-a48118bc72e7.html","2016-03-31 11:53:44 -0700","DDI-clinical-trial","evidence-supports","is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  ","Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.","","ncit:positive","ncit:quantitative",,"simvastatin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","digoxin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction",".4","SD","Oral","1","QD","Oral","10","UNK","UNK","UNK","UNK","UNK","UNK","UNK",".3ng//mL","UNK","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/50914a46-eab6-4c83-97cf-6ab0234c8126.html","2017-03-15 15:03:45 -0400","drug-drug-interaction","evidence-supports"," and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A. ","Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A (see CONTRAINDICATIONS). ","With drugs inhibiting CYP3A to a lesser, but still significant degree,","ncit:positive","ncit:Qualitative",,"ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"estazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 18:55:35 -0700","DDI-clinical-trial","evidence-challenges","in a maintenance trial of bipolar patients did not affect mean therapeutic lithium levels.      ","In vivo studies have revealed no effect of ziprasidone on the pharmacokinetics of estrogen or progesterone components. Ziprasidone at a dose of 20 mg twice daily did not affect the pharmacokinetics of concomitantly administered oral contraceptives, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg).","","ncit:negative","ncit:quantitative",,"ethinyl estradiol","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction",".03","ziprasidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","UNK","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:45:30 -0700","DDI-clinical-trial","evidence-challenges","","A single-dose interaction study with zolpidem tartrate 10 mg and fluoxetine 20 mg at steady-state levels in male volunteers did not demonstrate any clinically significant pharmacokinetic or pharmacodynamic interactions. ","When multiple doses of","ncit:negative","ncit:quantitative","id not demonstrate any clinically significant pharmacokinetic or pharmacodynamic interactions","zolpidem","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","10","fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 15:56:19 -0700","drug-drug-interaction","evidence-challenges","WARNINGS, Myopathy/Rhabdomyolysis .   ","Propranolol: In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of lovastatin and propranolol.","","ncit:negative","ncit:Qualitative","No clinically significant PK interaction with concomitant lovastatin and propranolol","propranolol","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","lovastatin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 16:07:41 -0700","drug-drug-interaction","evidence-challenges","Impact of Dabigatran on Other Drugs  ","In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine.","","ncit:negative","ncit:Qualitative","dabigatran did not meaningfully alter the pharmacokinetics of digoxin","dabigatran","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"digoxin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 15:45:57 -0700","DDI-clinical-trial","evidence-supports","","Ticagrelor: Administration of ticagrelor modestly increases plasma concentrations of dabigatran with the magnitude of increase dependent on the dose and timing of ticagrelor administration. When dabigatran etexilate 110 mg twice daily was coadministered with 90 mg oral ticagrelor twice daily, the AUCτ,ss and Cmax,ss of dabigatran increased by 26% and 29%, respectively."," When coadministered with a loading dose of 180 mg","ncit:positive","ncit:quantitative",,"ticagrelor","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","90","dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","110","BID","Oral","UNK","BID","Oral","UNK","UNK","26","Percent","Increase","UNK","UNK","UNK","29","Percent","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a0da0dba-a56d-486b-a45b-e8a7cdfbeac6.html","2016-05-10 10:40:54 -0700","DDI-clinical-trial","evidence-supports","  Oral contraceptives  ","Coadministration of oral contraceptives increased maximum plasma concentration by 6%, decreased clearance by 32%, and increased half-life by 16%.    Grapefruit juice    Coadministration of grapefruit juice increased the maximum plasma concentration of triazolam","","ncit:positive","ncit:quantitative",,"oral contraceptives","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","triazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","UNK","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","32","Percent","Decrease","6","Percent","Increase","16","Percent","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6.html","2016-03-14 13:58:35 -0700","DDI-clinical-trial","evidence-challenges","aripiprazole pharmacokinetics        ","The effects of ABILIFY on the exposures of other drugs are summarized in Figure 21. A population PK analysis in patients with major depressive disorder showed no substantial change in plasma concentrations of fluoxetine (20 mg/day or 40 mg/day), paroxetine CR (37.5 mg/day or 50 mg/day), or sertraline (100 mg/day or 150 mg/day) dosed to steady-state. The steady-state plasma concentrations of fluoxetine and norfluoxetine increased by about 18% and 36%, respectively, and concentrations of paroxetine decreased by about 27%. The steady-state plasma concentrations of sertraline and desmethylsertraline were not substantially changed when these antidepressant therapies were coadministered with aripiprazole.","","ncit:negative","ncit:quantitative","The steady-state plasma concentrations of sertraline and desmethylsertraline were not substantially changed when these antidepressant therapies were coadministered with aripiprazole.","ABILIFY","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","sertraline","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","100-150","Daily","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 15:37:23 -0700","drug-drug-interaction","evidence-challenges","by 53% and 56%, respectively.   ","Clarithromycin: Coadministered clarithromycin had no impact on the exposure to dabigatran.","","ncit:negative","ncit:Qualitative","clarithromycin had no impact on the exposure to dabigatran","dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","clarithromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/50914a46-eab6-4c83-97cf-6ab0234c8126.html","2017-03-15 15:03:45 -0400","drug-drug-interaction","evidence-supports",", isoniazide, and some macrolide antibiotics.  ","While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations. ","","ncit:positive","ncit:Qualitative","DELETE","estazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","carbamazepine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 16:15:09 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. ","Strong inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, erythromycin, and cobicistat-containing products), and grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin. (See CONTRAINDICATIONS, WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics.)","","ncit:positive","ncit:Qualitative","Boceprevir is a strong inhibitor of CYP3A4 and reduces the elimination of lovastatin","lovastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","boceprevir","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:26:13 -0400","DDI-clinical-trial","evidence-supports","or its metabolite, 2-hydroxy desipramine .  ","There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.","","ncit:positive","ncit:quantitative","DELETE","desipramine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","75","mCPP","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","150","BID","Oral","UNK","QD","Oral","UNK","UNK","44","Percent","Increase","UNK","UNK","UNK","48","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 14:46:01 -0500","drug-drug-interaction","evidence-supports","Inducers of CYP1A2 or Glucuronyl Transferase — "," Omeprazole and rifampin may cause an increase in olanzapine clearance. ","","ncit:positive","ncit:Qualitative","may cause an increase in olanzapine clearance","rifampin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"olanzapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/50914a46-eab6-4c83-97cf-6ab0234c8126.html","2017-03-15 14:52:59 -0400","drug-drug-interaction","evidence-supports"," is catalyzed by CYP3A. ","While no in vivo drug-drug interaction studies were conducted between estazolam and inhibitors/inducers of CYP3A, compounds that are potent CYP3A inhibitors (such as ketoconazole, itraconazole, nefazodone, fluvoxamine, and erythromycin) would be expected to increase plasma estazolam concentrations and CYP3A inducers (such as carbamazepine, phenytoin, rifampin and barbiturates) would be expected to decrease estazolam concentrations. ","","ncit:positive","ncit:Qualitative",,"estazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/aad8b373-0aec-4efb-8e61-3d8114b31127.html","2016-03-31 12:55:20 -0700","drug-drug-interaction","evidence-challenges","Pharmacokinetic data in the pediatric population are not available.   Drug-Drug Interactions:   ","Data from drug-drug interactions studies involving coadministration of gemfibrozil, niacin, itraconazole, erythromycin, tolbutamide or clopidogrel indicate that the PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with any of these drugs.","","ncit:negative","ncit:Qualitative","PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with niacin","fluvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","niacin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/39a5dae2-49f7-4662-9eac-aa7b4c7807a4.html","2017-03-15 15:18:23 -0400","drug-drug-interaction","evidence-supports","","When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.","","ncit:negative","ncit:Qualitative",,"olanzapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","eszopiclone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 18:16:48 -0700","DDI-clinical-trial","evidence-challenges","digoxin (0.375 mg q24h for 8 days).  ","Warfarin: Multiple oral doses of Zaleplon (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.","","ncit:negative","ncit:quantitative","did not affect the pharmacokinetics of warfarin","Zaleplon","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","warfarin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","25","SD","Oral","1","QD","UNK","13","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:22:02 -0700","drug-drug-interaction","evidence-supports","Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias.  ","Reduced cytochrome P450 2D6 isozyme activity drugs that inhibit this isozyme (e.g., fluoxetine and paroxetine) and certain other drugs (e.g., fluvoxamine, propranolol, and pindolol) appear to appreciably inhibit the metabolism of thioridazine. The resulting elevated levels of thioridazine would be expected to augment the prolongation of the QTc interval associated with thioridazine and may increase the risk of serious, potentially fatal, cardiac arrhythmias, such as Torsades de pointes type arrhythmias.","","ncit:positive","ncit:Qualitative","appear to appreciably inhibit the metabolism of thioridazine and result in elevated levels of thioridazine","propranolol","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"thioridazine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5429f134-839f-4ffc-9944-55f51238def8.html","2015-12-18 13:50:52 -0700","DDI-clinical-trial","evidence-supports","Strong CYP1A2 Inhibitors (e.g., Fluvoxamine )  ","SAPHRIS is metabolized by CYP1A2. Marginal increase of asenapine exposure was observed when SAPHRIS is used with fluvoxamine at 25 mg administered twice daily [see Clinical Pharmacology (12.3)","","ncit:positive","ncit:quantitative","Marginal increase of asenapine exposure","SAPHRIS","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","fluvoxamine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","25","UNK","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c6e131fe-e7df-4876-83f7-9156fc4e8228.html","2016-03-14 15:02:19 -0700","DDI-clinical-trial","evidence-supports","   7.8 Digoxin  ","When multiple doses of LIPITOR and digoxin were co-administered, steady state plasma digoxin concentrations increased by approximately 20%. Patients taking digoxin should be monitored appropriately","","ncit:positive","ncit:quantitative",,"digoxin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","LIPITOR","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","20","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 17:46:48 -0700","DDI-clinical-trial","evidence-challenges","50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration. The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug.  ","Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine. In addition, there was no pharmacodynamic interaction as a result of coadministration of zaleplon and venlafaxine ER.","","ncit:negative","ncit:quantitative","did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine","venlafaxine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","150","zaleplon","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","10","SD","Oral","1","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/50914a46-eab6-4c83-97cf-6ab0234c8126.html","2017-03-15 14:57:45 -0400","drug-drug-interaction","evidence-supports","estazolam is catalyzed by CYP3A. ","While no in vivo drug-drug interaction studies were conducted between estazolam and inhibitors/inducers of CYP3A, compounds that are potent CYP3A inhibitors (such as ketoconazole, itraconazole, nefazodone, fluvoxamine, and erythromycin) would be expected to increase plasma estazolam concentrations and CYP3A inducers (such as carbamazepine, phenytoin, rifampin and barbiturates) would be expected to decrease estazolam concentrations.","","ncit:positive","ncit:Qualitative",,"estazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","phenytoin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 14:09:54 -0500","DDI-clinical-trial","evidence-challenges","    Theophylline   ","When nefazodone (200 mg BID) was given to patients being treated with theophylline (600 to 1200 mg/day) for chronic obstructive pulmonary disease, there was no change in the steady-state pharmacokinetics of either nefazodone or theophylline. FEV1 measurements taken when theophylline and nefazodone were coadministered did not differ from baseline dosage (i.e., when theophylline was administered alone). Therefore, dosage adjustment is not necessary for either drug when coadministered.","","ncit:negative","ncit:quantitative",,"theophylline","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","600 to 1200","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","Daily","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:47:38 -0400","drug-drug-interaction","evidence-supports","7.1 Potential for Other Drugs to Affect LATUDA   ","LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)]. ","","ncit:positive","ncit:Qualitative",,"ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","","LATUDA","dikbD2R:drug-product","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 15:18:12 -0500","DDI-clinical-trial","evidence-challenges"," — ","Multiple doses of olanzapine (10 mg for 8 days) did not influence the kinetics of lithium. ","","ncit:negative","ncit:quantitative",,"lithium.","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","olanzapine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","10","UNK","Oral","UNK","UNK","Oral","8","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 14:23:33 -0500","DDI-clinical-trial","evidence-supports"," Cardiovascular-Active Drugs   ","Digoxin – When nefazodone (200 mg BID) and digoxin (0.2 mg QD) were coadministered for 9 days to healthy male volunteers (n = 18) who were phenotyped as CYP2D6 extensive metabolizers, Cmax, Cmin, and AUC of digoxin were increased by 29%, 27%, and 15%, respectively.","","ncit:positive","ncit:quantitative",,"nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","digoxin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction",".2","QD","Oral","9","BID","Oral","9","18","15","Percent","Increase","UNK","UNK","UNK","29","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c6e131fe-e7df-4876-83f7-9156fc4e8228.html","2016-03-14 14:49:42 -0700","drug-drug-interaction","evidence-supports","","Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR with several combinations of HIV protease inhibitors, as well as with the hepatitis C protease inhibitor telaprevir, compared to that of LIPITOR alone [","see      ","ncit:positive","ncit:Qualitative","Atorvastatin AUC was significantly increased with concomitant administration","Atorvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","telaprevir","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:22:02 -0700","drug-drug-interaction","evidence-supports","Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias.  ","Reduced cytochrome P450 2D6 isozyme activity drugs that inhibit this isozyme (e.g., fluoxetine and paroxetine) and certain other drugs (e.g., fluvoxamine, propranolol, and pindolol) appear to appreciably inhibit the metabolism of thioridazine. The resulting elevated levels of thioridazine would be expected to augment the prolongation of the QTc interval associated with thioridazine and may increase the risk of serious, potentially fatal, cardiac arrhythmias, such as Torsades de pointes type arrhythmias.","","ncit:positive","ncit:Qualitative","appear to appreciably inhibit the metabolism of thioridazine and result in elevated levels of thioridazine","pindolol","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"thioridazine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 21:24:45 -0400","DDI-clinical-trial","evidence-challenges","Drugs That Alter Renal Excretion ","Ibuprofen: Ibuprofen is known to affect renal function and, consequently, alter the renal excretion of other drugs. There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug. This was expected because zaleplon is primarily metabolized and renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose. ","","ncit:negative","ncit:quantitative","no apparent pharmacokinetic interaction","zaleplon","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","10","ibuprofen","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","600","SD","Oral","1","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 18:01:31 -0700","DDI-clinical-trial","evidence-supports","","Rifampin: CYP3A4 is ordinarily a minor metabolizing enzyme of zaleplon. Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%."," The coadministration of a potent CYP3A4 enzyme inducer, although not posing a safety concern, thus could lead to ineffectiveness of","ncit:positive","ncit:quantitative",,"zaleplon","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","rifampin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","600","UNK","Oral","UNK","QD","Oral","14","UNK","80","Percent","Decrease","UNK","UNK","UNK","80","Percent","Decrease","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c6e131fe-e7df-4876-83f7-9156fc4e8228.html","2016-03-14 14:46:09 -0700","DDI-clinical-trial","evidence-supports","","Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)]. ","","ncit:positive","ncit:quantitative","Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily)","Atorvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","80","clarithromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","500","UNK","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2017-03-16 18:04:26 -0400","drug-drug-interaction","evidence-supports"," — ","Multiple doses of olanzapine did not affect the pharmacokinetics of theophylline or its metabolites. ","","ncit:negative","ncit:Qualitative",,"theophylline","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","olanzapine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c6e131fe-e7df-4876-83f7-9156fc4e8228.html","2016-03-14 14:54:30 -0700","DDI-clinical-trial","evidence-supports","","Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)]. Therefore, in patients taking itraconazole, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)]. ","","ncit:positive","ncit:quantitative","Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg","itraconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","Atorvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","40","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e9481622-7cc6-418a-acb6-c5450daae9b0.html","2016-04-12 11:02:59 -0700","drug-drug-interaction","evidence-challenges","did not meaningfully alter the pharmacokinetics of apixaban .  ","In studies conducted in healthy subjects, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, atenolol, prasugrel, or acetylsalicylic acid.","","ncit:negative","ncit:Qualitative","pixaban did not meaningfully alter the pharmacokinetics of naproxen","apixaban","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"naproxen","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e9481622-7cc6-418a-acb6-c5450daae9b0.html","2016-04-12 14:04:43 -0400","drug-drug-interaction","evidence-challenges","did not meaningfully alter the pharmacokinetics of apixaban .  ","In studies conducted in healthy subjects, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, atenolol, prasugrel, or acetylsalicylic acid.","","ncit:negative","ncit:Qualitative","pixaban did not meaningfully alter the pharmacokinetics of atenolol","atenolol","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","apixaban","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 14:47:05 -0500","DDI-clinical-trial","evidence-challenges","are coadministered; plasma level monitoring for digoxin is recommended.  ","Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.","","ncit:negative","ncit:quantitative",,"nefazodone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","200","propranolol","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","BID","Oral","5.5","BID","Oral","5.5","18","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 15:08:12 -0500","DDI-clinical-trial","evidence-challenges","were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.  ","HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent","","ncit:negative","ncit:quantitative",,"pravastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","UNK","Oral","UNK","BID","Oral","6","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html","2015-11-29 18:15:29 -0500","drug-drug-interaction","evidence-challenges",". ","In a clinical study, subjects on stable doses of valproate had comparable valproate average plasma concentrations when INVEGA® 3–15 mg/day was added to their existing valproate treatment.","","ncit:negative","ncit:Qualitative","omparable valproate average plasma concentrations","valproate","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","INVEGA","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:53:19 -0700","drug-drug-interaction","evidence-challenges","Other Drugs with No Interactions with Zolpidem   ","A study involving cimetidine/zolpidem tartrate and ranitidine/zolpidem tartrate combinations revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem.","","ncit:negative","ncit:Qualitative","no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem.","zolpidem","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","cimetidine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a971ea18-40cf-4a01-b696-180ccc3fddb5.html","2016-02-29 16:08:19 -0500","drug-drug-interaction","evidence-supports","Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly.  ","Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs","","ncit:positive","ncit:Qualitative","results in increased plasma levels of both drugs","phenothiazines","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"propranolol","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6.html","2016-03-14 13:55:11 -0700","DDI-clinical-trial","evidence-supports","aripiprazole pharmacokinetics        ","The effects of ABILIFY on the exposures of other drugs are summarized in Figure 21. A population PK analysis in patients with major depressive disorder showed no substantial change in plasma concentrations of fluoxetine (20 mg/day or 40 mg/day), paroxetine CR (37.5 mg/day or 50 mg/day), or sertraline (100 mg/day or 150 mg/day) dosed to steady-state. The steady-state plasma concentrations of fluoxetine and norfluoxetine increased by about 18% and 36%, respectively, and concentrations of paroxetine decreased by about 27%. The steady-state plasma concentrations of sertraline and desmethylsertraline were not substantially changed when these antidepressant therapies were coadministered with aripiprazole.","","ncit:positive","ncit:quantitative","this was a pop pk study","paroxetine CR","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","37.5-50","ABILIFY","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","Daily","Oral","UNK","UNK","Oral","UNK","UNK","27","Percent","Decrease","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:45:30 -0700","DDI-clinical-trial","evidence-supports","20 mg at steady-state levels in male volunteers did not demonstrate any clinically significant pharmacokinetic or pharmacodynamic interactions. ","When multiple doses of zolpidem and fluoxetine were given at steady state and the concentrations evaluated in healthy females, an increase in the zolpidem half-life (17%) was observed. There was no evidence of an additive effect in psychomotor performance.","","ncit:positive","ncit:quantitative","in healthy females","fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","zolpidem","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","UNK","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","17","Percent","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:53:39 -0700","drug-drug-interaction","evidence-challenges","Other Drugs with No Interactions with Zolpidem   ","A study involving cimetidine/zolpidem tartrate and ranitidine/zolpidem tartrate combinations revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem.","","ncit:negative","ncit:Qualitative","no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem.","zolpidem","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","ranitidine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/fdbfe194-b845-42c5-bb87-a48118bc72e7.html","2016-03-31 12:23:25 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  ","Elevated plasma levels of HMG-CoA reductase inhibitory activity increases the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).] Concomitant use of drugs labeled as having a strong inhibitory effect on CYP3A4 is contraindicated [see Contraindications (4)]. If treatment with itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin must be suspended during the course of treatment.","","ncit:positive","ncit:Qualitative","strong inhibitor of CYP3A4 may elevate simvastatin plasma level","simvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","erythromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:50:16 -0400","drug-drug-interaction","evidence-supports","7.1 Potential for Other Drugs to Affect LATUDA   ","LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)]. ","","ncit:positive","ncit:Qualitative",,"LATUDA","dikbD2R:drug-product","dikbD2R:object-drug-of-interaction",,"atazanavir","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/fdbfe194-b845-42c5-bb87-a48118bc72e7.html","2016-03-31 12:38:39 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  ","Elevated plasma levels of HMG-CoA reductase inhibitory activity increases the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).] Concomitant use of drugs labeled as having a strong inhibitory effect on CYP3A4 is contraindicated [see Contraindications (4)]. If treatment with itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin must be suspended during the course of treatment.","","ncit:positive","ncit:Qualitative","strong inhibitor of CYP3A4 may elevate simvastatin plasma level","telithromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"simvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/44dcbf97-99ec-427c-ba50-207e0069d6d2.html","2016-03-31 13:20:20 -0400","drug-drug-interaction","evidence-challenges","   7.8 Warfarin   ","LIVALO had no significant pharmacokinetic interaction with R- and S- warfarin. LIVALO had no significant effect on prothrombin time (PT) and international normalized ratio (INR) when administered to patients receiving chronic warfarin treatment [see Clinical Pharmacology (12.3)]. However, patients receiving warfarin should have their PT and INR monitored when pitavastatin is added to their therapy. ","","ncit:negative","ncit:Qualitative","Pitavastatin had no significant pharmacokinetic interaction with R- and S- warfarin. and no significant effect on prothrombin time (PT) and international normalized ratio (INR) when administered to patients receiving chronic warfarin.Study details in section 12 Table 3","pitavastatin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"warfarin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 17:37:17 -0700","DDI-clinical-trial","evidence-challenges",", reflecting the absence of a role of CYP2D6 in zaleplon 's metabolism.  ","Thioridazine: Coadministration of single doses of Zaleplon 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration. The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug.","","ncit:negative","ncit:quantitative","no alteration of the pharmacokinetics of either drug.","Zaleplon","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","thioridazine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","50","SD","UNK","1","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 14:37:36 -0500","DDI-clinical-trial","evidence-challenges"," Cardiovascular-Active Drugs   ","Digoxin – When nefazodone (200 mg BID) and digoxin (0.2 mg QD) were coadministered for 9 days to healthy male volunteers (n = 18) who were phenotyped as CYP2D6 extensive metabolizers, Cmax, Cmin, and AUC of digoxin were increased by 29%, 27%, and 15%, respectively. Digoxin had no effects on the pharmacokinetics of nefazodone and its active metabolites. Because of the narrow therapeutic index of digoxin, caution should be exercised when nefazodone and digoxin are coadministered; plasma level monitoring for digoxin is recommended.","","ncit:negative","ncit:quantitative",,"digoxin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",".2","nefazodone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","200","BID","Oral","9","QD","Oral","9","18","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/39a5dae2-49f7-4662-9eac-aa7b4c7807a4.html","2016-05-09 19:27:24 -0400","drug-drug-interaction","evidence-challenges","."," When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.","","ncit:negative","ncit:Qualitative","eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine","olanzapine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"eszopiclone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:17:25 -0400","DDI-clinical-trial","evidence-supports","and alcohol in depressed patients is not advised.  ","Buspirone – In a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20 fold in Cmax and up to 50 fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine. With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%).","","ncit:positive","ncit:quantitative",,"nefazodone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","250","buspirone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","5","BID","Oral","Unk","BID","Oral","Unk","Unk","23","Percent","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e9481622-7cc6-418a-acb6-c5450daae9b0.html","2016-04-12 10:50:04 -0700","drug-drug-interaction","evidence-supports","7.2 Strong Dual Inducers of CYP3A4 and P-gp  ","Avoid concomitant use of ELIQUIS with strong dual inducers of CYP3A4 and P-gp (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban [see Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","phenytoin will decrease exposure to apixaban","phenytoin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"apixaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/fdbfe194-b845-42c5-bb87-a48118bc72e7.html","2016-03-31 12:22:09 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  ","Elevated plasma levels of HMG-CoA reductase inhibitory activity increases the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).] Concomitant use of drugs labeled as having a strong inhibitory effect on CYP3A4 is contraindicated [see Contraindications (4)]. If treatment with itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin must be suspended during the course of treatment.","","ncit:positive","ncit:Qualitative","strong inhibitor of CYP3A4 may elevate simvastatin plasma level","simvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","itraconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html","2015-11-29 18:21:18 -0500","DDI-clinical-trial","evidence-supports","have not been studied. The clinical relevance is unknown.  ","Co-administration of a single dose of INVEGA® 12 mg with divalproex sodium extended-release tablets (two 500 mg tablets once daily) resulted in an increase of approximately 50% in the Cmax and AUC of paliperidone. Dosage reduction for INVEGA® should be considered when INVEGA® is co-administered with valproate after clinical assessment.","","ncit:positive","ncit:quantitative",,"INVEGA","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","12","divalproex sodium","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","1000","SD","Oral","1","QD","Oral","UNK","UNK","50","Percent","Increase","UNK","UNK","UNK","50","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 16:26:31 -0700","drug-drug-interaction","evidence-supports","7.1 Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems  ","In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. The increases in exposure ranged from 30% to 160%. Significant increases in rivaroxaban exposure may increase bleeding risk [see Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","increases in rivaroxaban exposure","erythromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c6e131fe-e7df-4876-83f7-9156fc4e8228.html","2016-03-14 15:04:06 -0700","drug-drug-interaction","evidence-supports","   7.9 Oral Contraceptives  ","Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)]. These increases should be considered when selecting an oral contraceptive for a woman taking LIPITOR.","","ncit:positive","ncit:Qualitative","Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol","norethindrone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","LIPITOR","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:41:13 -0400","drug-drug-interaction","evidence-supports","","Valproate: It is not necessary to adjust the LATUDA dose when used concomitantly with valproate. A dedicated drug-drug interaction study has not been conducted with valproate and LATUDA. Based on pharmacokinetic data from the bipolar depression studies valproate levels were not affected by lurasidone, and lurasidone concentrations were not affected by valproate. ","","ncit:negative","ncit:Qualitative",,"valproate","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","lurasidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 18:04:06 -0700","DDI-clinical-trial","evidence-supports"," dose. ","Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor, produced a 34% increase in zaleplon's maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve. ","The magnitude of interaction with multiple doses of","ncit:positive","ncit:quantitative",,"zaleplon","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","10","erythromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","80","SD","Oral","1","SD","Oral","1","UNK","20","Percent","Increase","UNK","UNK","UNK","34","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:39:55 -0700","drug-drug-interaction","evidence-supports","CYP2D6 and CYP3A4 Inhibitors   ","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)].","","ncit:positive","ncit:Qualitative","escitalopram can increase clozapine levels","escitalopram","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/50914a46-eab6-4c83-97cf-6ab0234c8126.html","2017-03-15 14:57:45 -0400","drug-drug-interaction","evidence-supports","estazolam is catalyzed by CYP3A. ","While no in vivo drug-drug interaction studies were conducted between estazolam and inhibitors/inducers of CYP3A, compounds that are potent CYP3A inhibitors (such as ketoconazole, itraconazole, nefazodone, fluvoxamine, and erythromycin) would be expected to increase plasma estazolam concentrations and CYP3A inducers (such as carbamazepine, phenytoin, rifampin and barbiturates) would be expected to decrease estazolam concentrations.","","ncit:positive","ncit:Qualitative",,"estazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","erythromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:41:56 -0700","drug-drug-interaction","evidence-supports","CYP2D6 and CYP3A4 Inhibitors   ","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)]","","ncit:positive","ncit:Qualitative","Quinidine can increase clozapine levels","quinidine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 14:07:13 -0500","DDI-clinical-trial","evidence-challenges","    Cimetidine   ","When nefazodone (200 mg BID) and cimetidine (300 mg QID) were coadministered for one week, no change in the steady-state pharmacokinetics of either nefazodone or cimetidine was observed compared to each dosed alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.","","ncit:negative","ncit:quantitative",,"nefazodone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","200","cimetidine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","300","BID","Oral","7","QID","Oral","7","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d78e9639-6fab-4a78-8b29-6991a18ae6c6.html","2016-02-19 17:46:51 -0500","drug-drug-interaction","evidence-supports","ity of this enzyme, so-called “poor” metabolizers. Among other populations the prevalence is not known. Poor metabolizers demonstrate higher plasma concentrations of antipsychotic drugs at usual doses, which may correlate with emergence of side effects. ","In one study of 45 elderly patients suffering from dementia treated with perphenazine, the 5 patients who were prospectively identified as poor P450 2D6 metabolizers had reported significantly greater side effects during the first 10 days of treatment than the 40 extensive metabolizers, following which the groups tended to converge. Prospective phenotyping of elderly patients prior to antipsychotic treatment may identify those at risk for adverse events.    The concomitant administration of other drugs that inhibit the activity of P450 2D6 may acutely increase plasma concentrations of antipsychotics. Among these are tricyclic antidepressants and selective serotonin reuptake inhibitors, e.g., fluoxetine, sertraline and paroxetine. When prescribing these drugs to patients already receiving antipsychotic therapy, close monitoring is essential and dose reduction may become necessary to avoid toxicity. Lower doses than usually prescribed for either the antipsychotic or the other drug may be required.","","ncit:positive","ncit:Qualitative","may acutely increase plasma concentrations of antipsychotics.","fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"perphenazine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:37:32 -0700","DDI-clinical-trial","evidence-supports","  Fluvoxamine  ","The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. Fluvoxamine and thioridazine should not be coadministered.","","ncit:positive","ncit:quantitative",,"mesoridazine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","25","Fluvoxamine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","BID","Oral","7","10","3","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 17:50:18 -0700","DDI-clinical-trial","evidence-challenges","50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration. The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug.  ","Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine. In addition, there was no pharmacodynamic interaction as a result of coadministration of zaleplon and venlafaxine ER.","","ncit:negative","ncit:quantitative","did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine","zaleplon","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","10","venlafaxine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","150","UNK","Oral","UNK","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c6e131fe-e7df-4876-83f7-9156fc4e8228.html","2016-03-14 15:25:58 -0700","DDI-clinical-trial","evidence-supports","TABLE 3. Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin           ","Co-administered drug and dosing regimen  Atorvastatin   Dose (mg)  Change in AUC*  Change in Cmax*    *      Data given as x-fold change represent a simple ratio between co-administration and atorvastatin alone (i.e., 1-fold = no change). Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change).   †      See Sections 5.1 and 7 for clinical significance.   ‡      The dose of saquinavir plus ritonavir in this study is not the clinically used dose. The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, caution should be applied and the lowest dose necessary should be used.   §      Greater increases in AUC (up to 2.5 fold) and/or Cmax (up to 71%) have been reported with excessive grapefruit consumption (≥ 750 mL – 1.2 liters per day).   ¶      Single sample taken 8–16 h post dose.   #      Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.     †Cyclosporine 5.2 mg/kg/day, stable dose  10 mg QD for 28 days  ↑ 8.7 fold  ↑ 10.7 fold","","ncit:positive","ncit:quantitative","Table 3","atorvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","10","Cyclosporine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","5.2mg/kg/day","QD","Oral","28","Daily","Oral","UNK","UNK","8.7","Fold","Increase","UNK","UNK","UNK","10.7","Fold","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 15:52:59 -0700","DDI-clinical-trial","evidence-supports","","When coadministered with a loading dose of 180 mg ticagrelor, the AUCτ,ss and Cmax,ss of dabigatran increased by 49% and 65%, respectively","; but when","ncit:positive","ncit:quantitative",,"ticagrelor","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","180","dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","SD","Oral","1","UNK","49","Percent","Increase","UNK","UNK","UNK","65","UNK","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 17:48:17 -0700","DDI-clinical-trial","evidence-challenges","","In addition, there were no significant pharmacokinetic interactions observed in studies comparing concomitant rivaroxaban 20 mg and 7.5 mg single dose of midazolam ","(substrate of CYP3A4), 0.375 mg once-daily dose of","ncit:negative","ncit:quantitative","no significant pharmacokinetic interactions observed","midazolam","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","7.5","rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","20","UNK","Oral","UNK","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c6e131fe-e7df-4876-83f7-9156fc4e8228.html","2016-03-30 18:03:19 -0400","drug-drug-interaction","evidence-challenges","   7.10 Warfarin  ","LIPITOR had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.","","ncit:negative","ncit:Qualitative","Concomitant Lipitor and warfarin had no clinically significant effect on prothrombin time","warfarin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","LIPITOR","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2017-03-16 18:01:57 -0400","DDI-clinical-trial","evidence-supports","    Lorazepam (IM) — ","Administration of intramuscular lorazepam (2 mg) 1 hour after intramuscular olanzapine for injection (5 mg) did not significantly affect the pharmacokinetics of olanzapine, unconjugated lorazepam, or total lorazepam.","","ncit:negative","ncit:quantitative",,"lorazepam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","2","olanzapine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","5","SD","IV","1","SD","IV","1","Unk","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 17:19:40 -0500","DDI-clinical-trial","evidence-challenges","F","luoxetine: A single 3 mg dose of iloperidone had no effect on the pharmacokinetics of fluoxetine (20 mg twice daily). ","","ncit:negative","ncit:quantitative",,"iloperidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","3","fluoxetine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","20","BID","Oral","UNK","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:51:51 -0700","DDI-clinical-trial","evidence-supports",", a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamic effects of zolpidem .  ","A single-dose interaction study with zolpidem tartrate 5 mg and ketoconazole, a potent CYP3A4 inhibitor, given as 200 mg twice daily for 2 days increased Cmax of zolpidem (30%) and the total AUC of zolpidem (70%) compared to zolpidem alone and prolonged the elimination half-life (30 %) along with an increase in the pharmacodynamic effects of zolpidem. Consideration should be given to using a lower dose of zolpidem when ketoconazole and zolpidem are given together.","","ncit:positive","ncit:quantitative",,"ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","zolpidem","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","5","SD","Oral","1","BID","Oral","2","UNK","70","UNK","Increase","UNK","UNK","UNK","30","Percent","Increase","30","Percent","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 16:12:47 -0500","DDI-clinical-trial","evidence-challenges","","Nefazodone plasma concentrations were unaffected by alprazolam. ","If","ncit:negative","ncit:quantitative",,"alprazolam","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","1","Nefazodone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","200","BID","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 16:39:52 -0700","DDI-clinical-trial","evidence-supports","increased by 160% and 70%, respectively. Similar increases in pharmacodynamic effects were also observed.   ","Ritonavir (combined P-gp and strong CYP3A4 inhibitor): Single-dose rivaroxaban AUC and Cmax increased by 150% and 60%, respectively. Similar increases in pharmacodynamic effects were also observed.","","ncit:positive","ncit:quantitative",,"rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","Ritonavir","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","150","Percent","Increase","UNK","UNK","UNK","60","UNK","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/39a5dae2-49f7-4662-9eac-aa7b4c7807a4.html","2017-03-15 15:18:23 -0400","drug-drug-interaction","evidence-supports","","CYP3A4 is a major metabolic pathway for elimination of eszopiclone. The exposure of eszopiclone was increased by coadministration of ketoconazole, a potent inhibitor of CYP3A4. ","Other strong inhibitors of CYP3A4 (e.g.,","ncit:positive","ncit:Qualitative","DELETE","eszopiclone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 17:24:30 -0500","DDI-clinical-trial","evidence-challenges"," –"," When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine.","","ncit:negative","ncit:quantitative",,"nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","norfluoxetine","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","20","QD","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 13:40:46 -0500","DDI-clinical-trial","evidence-challenges","dosage should be guided by usual clinical practices.  ","Desipramine – When nefazodone (150 mg BID) and desipramine (75 mg QD) were administered together there were no changes in the pharmacokinetics of desipramine or its metabolite, 2-hydroxy desipramine. ","","ncit:negative","ncit:quantitative",,"2-hydroxy desipramine.","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","75","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","150","QD","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 16:15:52 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. ","Strong inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, erythromycin, and cobicistat-containing products), and grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin. (See CONTRAINDICATIONS, WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics.)","","ncit:positive","ncit:Qualitative","Teleprevir is a strong inhibitor of CYP3A4 and reduces the elimination of lovastatin","lovastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","telaprevir","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 16:44:38 -0500","drug-drug-interaction","evidence-supports","  Pindolol  ","Concurrent administration of pindolol and thioridazine have resulted in moderate, dose related increases in the serum levels of thioridazine and two of its metabolites, as well as higher than expected serum pindolol levels. Pindolol and thioridazine should not be coadministered.","","ncit:positive","ncit:Qualitative","dose related increases in the serum levels of thioridazine and two of its metabolites,","pindolol","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"thioridazine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a4ee3907-45d4-41b9-af8a-39a9966cd533.html","2016-05-10 13:18:17 -0400","drug-drug-interaction","evidence-challenges","   Drug Interactions  ","The pharmacokinetic profile of temazepam does not appear to be altered by orally administered cimetidine dosed according to labeling.","","ncit:negative","ncit:Qualitative","harmacokinetic profile of temazepam does not appear to be altered by orally administered cimetidine","cimetidine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"temazepam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-12 10:33:55 -0700","DDI-clinical-trial","evidence-challenges",": "," Enoxaparin 40 mg given subcutaneously for 3 days with the last dose given 24 hours before a single dose of PRADAXA had no impact on the exposure to dabigatran or the coagulation measures aPTT, ECT, or TT","","ncit:negative","ncit:quantitative","enoxaparin had no impact on the exposure to dabigatran","dabigatran","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","Enoxaparin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","SD","Oral","1","UNK","UNK","3","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 17:07:38 -0500","DDI-clinical-trial","evidence-supports","metabolite 1-pyrimidinylpiperazine.  ","With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%)","","ncit:positive","ncit:quantitative",,"hydroxynefazodone","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","250","buspirone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","5","BID","Oral","UNK","BID","Oral","UNK","UNK","17","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 14:46:01 -0500","drug-drug-interaction","evidence-supports"," —"," Omeprazole and rifampin may cause an increase in olanzapine clearance. ","","ncit:positive","ncit:Qualitative","may cause an increase in olanzapine clearance.","Omeprazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"olanzapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:07:08 -0400","DDI-clinical-trial","evidence-supports","were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.  ","HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent.","","ncit:positive","ncit:quantitative","entered plasma concentration increase as AUC","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","simvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","40","SD","Oral","1","BID","Oral","6","UNK","20","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 17:35:40 -0500","DDI-clinical-trial","evidence-supports","in ‘Poor Metabolizers’ and Potential Interaction With Drugs That Inhibit and/or Are Metabolized by Cytochrome P450 Isozymes.   Fluoxetine –  ","When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively","","ncit:positive","ncit:quantitative",,"fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","triazole-dione","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","200","BID","Oral","UNK","QD","Oral","UNK","UNK","1.3","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:33:50 -0700","drug-drug-interaction","evidence-supports","","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.)",". and decreased by the prototype CYP3A4 inducers (e..g,","ncit:positive","ncit:Qualitative","quetiapine exposure is increased by CYP3A4 inhibitors","Quetiapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 14:41:53 -0500","DDI-clinical-trial","evidence-supports","are coadministered; plasma level monitoring for digoxin is recommended.  ","Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol.","","ncit:positive","ncit:quantitative",,"4-hydroxypropranolol","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","40","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","BID","Oral","5.5","BID","Oral","5.5","18","UNK","UNK","UNK","UNK","UNK","UNK","14","Percent","Decrease","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/aad8b373-0aec-4efb-8e61-3d8114b31127.html","2016-03-31 12:59:55 -0700","drug-drug-interaction","evidence-challenges","fluvastatin sodium extended-release tablets, 80 mg QD for 19 days  ↓2%  ↑27%      ","Data from drug-drug interaction studies involving fluvastatin and coadministration of either gemfibrozil, tolbutamide or losartan indicate that the PK disposition of either gemfibrozil, tolbutamide or losartan is not significantly altered when coadministered with fluvastatin","","ncit:negative","ncit:Qualitative","PK disposition of  tolbutamide is not significantly altered when coadministered with fluvastatin.","fluvastatin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"tolbutamide","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6.html","2016-03-14 13:48:36 -0700","DDI-clinical-trial","evidence-supports","aripiprazole pharmacokinetics        ","The effects of ABILIFY on the exposures of other drugs are summarized in Figure 21. A population PK analysis in patients with major depressive disorder showed no substantial change in plasma concentrations of fluoxetine (20 mg/day or 40 mg/day), paroxetine CR (37.5 mg/day or 50 mg/day), or sertraline (100 mg/day or 150 mg/day) dosed to steady-state. The steady-state plasma concentrations of fluoxetine and norfluoxetine increased by about 18% and 36%, respectively, and concentrations of paroxetine decreased by about 27%. The steady-state plasma concentrations of sertraline and desmethylsertraline were not substantially changed when these antidepressant therapies were coadministered with aripiprazole.","","ncit:positive","ncit:quantitative","this was a pop pk study","ABILIFY","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","fluoxetine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","20-40","Daily","Oral","UNK","UNK","Oral","UNK","UNK","18","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:49:24 -0700","DDI-clinical-trial","evidence-supports","detected on subjective drowsiness, postural sway, or psychomotor performance.  ","A single-dose interaction study with zolpidem tartrate 10 mg and rifampin 600 mg at steady-state levels in female subjects showed significant reductions of the AUC (-73%), Cmax (-58%), and T1/2 (-36 %) of zolpidem together with significant reductions in the pharmacodynamic effects of zolpidem tartrate. Rifampin, a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamic effects of zolpidem.","","ncit:positive","ncit:quantitative",,"rifampin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","600","zolpidem","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","10","SD","Oral","1","UNK","Oral","UNK","UNK","73","Percent","Decrease","UNK","UNK","UNK","58","Percent","Decrease","36","Percent","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2017-03-16 17:21:10 -0400","DDI-clinical-trial","evidence-supports","or its metabolite, 2-hydroxy desipramine .  ","There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.","","ncit:positive","ncit:quantitative","DELETE","desipramine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","75","HO-NEF","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","150","BID","Oral","UNK","QD","Oral","UNK","UNK","19","Percent","Decrease","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html","2015-11-29 16:36:20 -0700","DDI-clinical-trial","evidence-supports","is not recommended.   Valproate   ","Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (n=21). However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone. Dose adjustment for valproate is not recommended.","","ncit:positive","ncit:quantitative",,"risperidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","4","valproate","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","1000","Daily","Oral","UNK","QD","Oral","UNK","21","UNK","UNK","UNK","UNK","UNK","UNK","20","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/fdbfe194-b845-42c5-bb87-a48118bc72e7.html","2016-03-31 12:22:09 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  ","Elevated plasma levels of HMG-CoA reductase inhibitory activity increases the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).] Concomitant use of drugs labeled as having a strong inhibitory effect on CYP3A4 is contraindicated [see Contraindications (4)]. If treatment with itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin must be suspended during the course of treatment.","","ncit:positive","ncit:Qualitative","strong inhibitor of CYP3A4 may elevate simvastatin plasma level","ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"simvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2017-03-16 18:04:26 -0400","drug-drug-interaction","evidence-supports"," — ","Multiple doses of olanzapine did not influence the kinetics of biperiden. ","","ncit:negative","ncit:Qualitative",,"biperiden","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","olanzapine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:34:13 -0700","DDI-clinical-trial","evidence-supports","  Fluvoxamine  ","The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. Fluvoxamine and thioridazine should not be coadministered.","","ncit:positive","ncit:quantitative",,"thioridazine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","Fluvoxamine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","25","UNK","Oral","UNK","BID","Oral","7","10","3","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c6e131fe-e7df-4876-83f7-9156fc4e8228.html","2016-03-14 14:57:35 -0700","DDI-clinical-trial","evidence-supports","","Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. The co-administration of LIPITOR with cyclosporine should be avoided ","[see","ncit:positive","ncit:quantitative","Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone","atorvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","10","cyclosporine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","5.2 mg/kg/day","UNK","Oral","UNK","Daily","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 16:26:31 -0700","drug-drug-interaction","evidence-supports","7.1 Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems  ","In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. The increases in exposure ranged from 30% to 160%. Significant increases in rivaroxaban exposure may increase bleeding risk [see Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","increases in rivaroxaban exposure","rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","clarithromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 17:35:54 -0700","drug-drug-interaction","evidence-challenges","."," In a single-dose drug interaction study there were no pharmacokinetic or pharmacodynamic interactions observed after concomitant administration of naproxen or aspirin (acetylsalicylic acid) with XARELTO.","","ncit:negative","ncit:Qualitative","no pharmacokinetic or pharmacodynamic interactions observed after concomitant administration of naproxen or aspirin (acetylsalicylic acid) with XARELTO.","XARELTO","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","naproxen","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 19:04:34 -0700","DDI-clinical-trial","evidence-challenges","in a maintenance trial of bipolar patients did not affect mean therapeutic valproate levels.     ","Population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam.         The absolute bioavailability of a 20 mg dose under fed conditions is approximately 60%. The absorption of ziprasidone is increased up to two-fold in the presence of food","","ncit:negative","ncit:quantitative",,"propranolol","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","ziprasidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a0da0dba-a56d-486b-a45b-e8a7cdfbeac6.html","2016-05-10 10:30:28 -0700","DDI-clinical-trial","evidence-supports","  Macrolide Antibiotics  ","Coadministration of erythromycin increased the maximum plasma concentration of triazolam by 46%, decreased clearance by 53%, and increased half-life by 35%; caution and consideration of appropriate triazolam dose reduction are recommended. Similar caution should be observed during coadministration with clarithromycin and other macrolide antibiotics.","","ncit:positive","ncit:quantitative",,"triazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","erythromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","53","Percent","Decrease","46","Percent","Increase","35","Percent","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/39a5dae2-49f7-4662-9eac-aa7b4c7807a4.html","2017-03-15 15:14:37 -0400","DDI-clinical-trial","evidence-supports","decreased each other's C max by 22%. ","Coadministration of eszopiclone 3 mg to subjects receiving ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days, resulted in a 2.2-fold increase in exposure to eszopiclone. Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respectively. LUNESTA would not be expected to alter the clearance of drugs metabolized by common CYP450 enzymes [see Warnings and Precautions (5.7), Dosage and Administration (2.3)]. ","","ncit:positive","ncit:quantitative",,"ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","400","eszopiclone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","3","UNK","Oral","5","Daily","Oral","5","UNK","2.2","Fold","Increase","UNK","UNK","UNK","1.4","Fold","Increase","1.3","Fold","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:40:30 -0700","drug-drug-interaction","evidence-supports","CYP2D6 and CYP3A4 Inhibitors   ","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)","","ncit:positive","ncit:Qualitative","paroxetine can increase clozapine levels","paroxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html","2017-03-16 18:10:23 -0400","DDI-clinical-trial","evidence-supports","should be re-evaluated and decreased if necessary.  ","Paliperidone is metabolized to a limited extent by CYP2D6 [see Clinical Pharmacology (12.3)]. In an interaction study in healthy subjects in which a single 3 mg dose of INVEGA® was administered concomitantly with 20 mg per day of paroxetine (a potent CYP2D6 inhibitor), paliperidone exposures were on average 16% (90% CI: 4, 30) higher in CYP2D6 extensive metabolizers. Higher doses of paroxetine have not been studied. The clinical relevance is unknown.","","ncit:negative","ncit:quantitative",,"paliperidone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","20","INVEGA","dikbD2R:drug-product","dikbD2R:precipitant-drug-of-interaction","3","Daily","Oral","Unk","SD","Oral","1","Unk","16","Percent","Increase","Unk","UNK","UNK","Unk","UNK","UNK","Unk","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 17:32:29 -0700","DDI-clinical-trial","evidence-challenges","75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration. The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug.  ","Paroxetine: Coadministration of a single dose of Zaleplon 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance. Additionally, paroxetine did not alter the pharmacokinetics of Zaleplon, reflecting the absence of a role of CYP2D6 in zaleplon's metabolism.","","ncit:negative","ncit:quantitative","paroxetine did not alter the pharmacokinetics of Zaleplon, reflecting the absence of a role of CYP2D6 in zaleplon's metabolism.","zaleplon","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","20","paroxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","SD","Oral","1","Daily","Oral","7","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 15:14:12 -0500","drug-drug-interaction","evidence-supports","are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.  ","Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.","","ncit:positive","ncit:Qualitative","small decreases in the steady-state plasma concentrations","triazole-dione","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","","Lithium","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 19:00:54 -0700","DDI-clinical-trial","evidence-challenges","dextromethorphan / dextrorphan ratio.     ","A pharmacokinetic interaction of ziprasidone with valproate is unlikely due to the lack of common metabolic pathways for the two drugs. Ziprasidone dosed adjunctively to valproate in a maintenance trial of bipolar patients did not affect mean therapeutic valproate levels.","","ncit:negative","ncit:quantitative",,"ziprasidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","valproate","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e9481622-7cc6-418a-acb6-c5450daae9b0.html","2016-04-12 11:01:28 -0700","drug-drug-interaction","evidence-challenges","and Drug Interactions (7) ] .  ","In dedicated studies conducted in healthy subjects, famotidine, atenolol, prasugrel, and enoxaparin did not meaningfully alter the pharmacokinetics of apixaban.","","ncit:negative","ncit:Qualitative","atenolol did not meaningfully alter the pharmacokinetics of apixaban","apixaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","atenolol","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/520428f1-2cd5-447f-8782-c8505ce65b72.html","2016-03-30 16:14:20 -0700","drug-drug-interaction","evidence-supports","is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. ","Strong inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, erythromycin, and cobicistat-containing products), and grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin. (See CONTRAINDICATIONS, WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics.)","","ncit:positive","ncit:Qualitative","Telithromycin is a strong inhibitor of CYP3A4 and reduces the elimination of lovastatin","telithromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"lovastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ba74e3cd-b06f-4145-b284-5fd6b84ff3c9.html","2016-04-11 16:05:23 -0700","drug-drug-interaction","evidence-challenges","I","n clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine.","","ncit:negative","ncit:Qualitative","dabigatran did not meaningfully alter the pharmacokinetics of atorvastatin","atorvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","dabigatran","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 15:21:48 -0500","DDI-clinical-trial","evidence-challenges"," — ","Olanzapine (10 mg daily for 2 weeks) did not affect the steady state plasma concentrations of valproate",". Therefore, concomitant","ncit:negative","ncit:quantitative",,"Olanzapine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","10","valproate","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","QD","Oral","14","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 18:09:38 -0700","DDI-clinical-trial","evidence-challenges","is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known. "," There is no pharmacokinetic interaction between zaleplon and diphenhydramine following the administration of a single dose (10 mg and 50 mg, respectively) of each drug. However, because both of these compounds have CNS effects, an additive pharmacodynamic effect is possible.","","ncit:negative","ncit:quantitative","no pharmacokinetic interaction between zaleplon and diphenhydramine","zaleplon","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","10","diphenhydramine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","50","SD","Oral","1","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2017-03-16 17:58:08 -0400","drug-drug-interaction","evidence-supports"," — ","Warfarin (20 mg single dose) did not affect olanzapine pharmacokinetics ","","ncit:negative","ncit:Qualitative","Single dose warfarin did not affect olanzapine pharmacokinetics","Warfarin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"olanzapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 16:42:40 -0700","DDI-clinical-trial","evidence-supports","increased by 150% and 60%, respectively. Similar increases in pharmacodynamic effects were also observed.   ","Clarithromycin (combined P-gp and strong CYP3A4 inhibitor): Single-dose rivaroxaban AUC and Cmax increased by 50% and 40%, respectively. The smaller increases in exposure observed for clarithromycin compared to ketoconazole or ritonavir may be due to the relative difference in P-gp inhibition.","","ncit:positive","ncit:quantitative",,"clarithromycin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","50","UNK","Increase","UNK","UNK","UNK","40","UNK","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:32:16 -0700","drug-drug-interaction","evidence-supports"," is not known.","    Rifampin    Rifampin, a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamic effects of zolpidem. Use of Rifampin in combination with zolpidem may decrease the efficacy of zolpidem.","","ncit:positive","ncit:Qualitative","significantly reduced the exposure to","Rifampin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"zolpidem","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:50:16 -0400","drug-drug-interaction","evidence-supports","7.1 Potential for Other Drugs to Affect LATUDA   ","LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)]. ","","ncit:positive","ncit:Qualitative",,"fluconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","","LATUDA","dikbD2R:drug-product","dikbD2R:object-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 16:49:58 -0500","DDI-clinical-trial","evidence-supports","","Paroxetine: Co-administration of paroxetine (20 mg/day for 5 to 8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18 to 65 years resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. ","When","ncit:positive","ncit:quantitative",,"iloperidone","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","8 or 12","paroxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","BID","Oral","UNK","Daily","Oral","5 to 8","UNK","UNK","UNK","UNK","UNK","UNK","UNK","1.6","Fold","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:47:38 -0400","drug-drug-interaction","evidence-supports","7.1 Potential for Other Drugs to Affect LATUDA   ","LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)]. ","","ncit:positive","ncit:Qualitative",,"LATUDA","dikbD2R:drug-product","dikbD2R:object-drug-of-interaction",,"rifampin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:45:41 -0700","drug-drug-interaction","evidence-supports","potentiated the cognitive and motor effects of alcohol in a clinical trial in subjects with selected psychotic disorders, and alcoholic beverages should be limited while taking quetiapine .  ","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.)","","ncit:positive","ncit:Qualitative","quetiapine exposure is increased by CYP3A4 inhibitors","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"Quetiapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d76d5540-7bae-4719-8166-f2a9106338df.html","2016-05-09 19:47:38 -0700","DDI-clinical-trial","evidence-supports",". The effect of inhibitors of other P450 enzymes on the pharmacokinetics of zolpidem is unknown.  ","A single-dose interaction study with zolpidem tartrate 10 mg and itraconazole 200 mg at steady-state levels in male volunteers resulted in a 34% increase in AUC0–∞ of zolpidem tartrate. There were no pharmacodynamic effects of zolpidem detected on subjective drowsiness, postural sway, or psychomotor performance.","","ncit:positive","ncit:quantitative",,"itraconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","zolpidem","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","10","SD","Oral","1","UNK","Oral","UNK","UNK","34","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a0da0dba-a56d-486b-a45b-e8a7cdfbeac6.html","2016-05-10 13:45:18 -0400","DDI-clinical-trial","evidence-supports","  Ranitidine  ","Coadministration of ranitidine increased the maximum plasma concentration of triazolam by 30%, increased the area under the concentration curve by 27%, and increased half-life by 3.3%. Caution is recommended during coadministration with triazolam.","","ncit:positive","ncit:quantitative",,"triazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","UNK","ranitidine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","27","Percent","Increase","UNK","UNK","UNK","30","Percent","Increase","3.3","Percent","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 16:35:23 -0500","DDI-clinical-trial","evidence-supports","elimination and cause increased blood levels.   ","Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.","","ncit:positive","ncit:quantitative",,"P88","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","3","ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","SD","Oral","1","BID","Oral","4","19","55","Percent","Increase","UNKUNUNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/44dcbf97-99ec-427c-ba50-207e0069d6d2.html","2016-03-31 10:15:25 -0700","drug-drug-interaction","evidence-supports","   7.3 Rifampin   ","Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","Rifampin significantly increased pitavastatin exposure. Study details in section 12 Table 3","Rifampin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"pitavastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/10db92f9-2300-4a80-836b-673e1ae91610.html","2016-05-01 17:53:05 -0700","DDI-clinical-trial","evidence-challenges","I","n addition, there were no significant pharmacokinetic interactions observed in studies comparing concomitant rivaroxaban 20 mg and 7.5 mg single dose of midazolam (substrate of CYP3A4), 0.375 mg once-daily dose of digoxin (substrate of P-gp), ","or 20 mg once daily dose of","ncit:negative","ncit:quantitative","no significant pharmacokinetic interactions observed","digoxin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",".375","rivaroxaban","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","20","UNK","Oral","UNK","QD","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:20:16 -0700","drug-drug-interaction","evidence-supports","Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias.  ","Reduced cytochrome P450 2D6 isozyme activity drugs that inhibit this isozyme (e.g., fluoxetine and paroxetine) and certain other drugs (e.g., fluvoxamine, propranolol, and pindolol) appear to appreciably inhibit the metabolism of thioridazine. The resulting elevated levels of thioridazine would be expected to augment the prolongation of the QTc interval associated with thioridazine and may increase the risk of serious, potentially fatal, cardiac arrhythmias, such as Torsades de pointes type arrhythmias.","","ncit:positive","ncit:Qualitative","appears to appreciably inhibit the metabolism of thioridazine and result in elevated levels of thioridazine","thioridazine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","paroxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 13:50:15 -0500","DDI-clinical-trial","evidence-challenges","are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.  ","Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.","","ncit:negative","ncit:quantitative",,"Lithium","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","500","nefazodone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","BID","Oral","5","BID","Oral","5","13","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2017-03-16 11:28:44 -0400","drug-drug-interaction","evidence-supports","fluoxetine (20 mg twice daily).   ","Midazolam (a sensitive CYP 3A4 substrate): A study in patients with schizophrenia showed a less than 50% increase in midazolam total exposure at iloperidone steady state (14 days of oral dosing at up to 10 mg iloperidone twice daily) and no effect on midazolam Cmax. Thus, an interaction between iloperidone and other CYP3A4 substrates is unlikely.","","ncit:positive","ncit:Qualitative","less than 50% increase in midazolam total exposure","midazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","iloperidone","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/50914a46-eab6-4c83-97cf-6ab0234c8126.html","2017-03-15 14:57:45 -0400","drug-drug-interaction","evidence-supports","estazolam is catalyzed by CYP3A. ","While no in vivo drug-drug interaction studies were conducted between estazolam and inhibitors/inducers of CYP3A, compounds that are potent CYP3A inhibitors (such as ketoconazole, itraconazole, nefazodone, fluvoxamine, and erythromycin) would be expected to increase plasma estazolam concentrations and CYP3A inducers (such as carbamazepine, phenytoin, rifampin and barbiturates) would be expected to decrease estazolam concentrations. ","","ncit:positive","ncit:Qualitative",,"estazolam","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","fluvoxamine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:45:41 -0700","drug-drug-interaction","evidence-supports","potentiated the cognitive and motor effects of alcohol in a clinical trial in subjects with selected psychotic disorders, and alcoholic beverages should be limited while taking quetiapine .  ","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.)","","ncit:positive","ncit:Qualitative","quetiapine exposure is increased by CYP3A4 inhibitors","Quetiapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","ritonavir","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2017-03-16 11:50:16 -0400","drug-drug-interaction","evidence-supports","7.1 Potential for Other Drugs to Affect LATUDA   ","LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see Dosage and Administration (2.5)]. ","","ncit:positive","ncit:Qualitative",,"LATUDA","dikbD2R:drug-product","dikbD2R:object-drug-of-interaction",,"carbamazepine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/aad8b373-0aec-4efb-8e61-3d8114b31127.html","2016-03-30 15:06:21 -0700","drug-drug-interaction","evidence-supports","   7.1 Cyclosporine  ","Cyclosporine coadministration increases fluvastatin exposure. Therefore, in patients taking cyclosporine, therapy should be limited to fluvastatin 20 mg twice daily [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].","","ncit:positive","ncit:Qualitative","Concomitant cyclosporin increases fluvastatin exposure. Details in Section 12 Table 3","Cyclosporine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"fluvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:45:41 -0700","drug-drug-interaction","evidence-supports","","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.). and decreased by the prototype CYP3A4 inducers (e..g, phenytoin, carbamazepine, rifampin, avasimibe, St. John’s wort etc.)."," Dose adjustment of","ncit:positive","ncit:Qualitative","quetiapine exposure is decreased by CYP3A4 inducers","rifampin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"Quetiapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c6e131fe-e7df-4876-83f7-9156fc4e8228.html","2016-03-14 14:59:55 -0700","drug-drug-interaction","evidence-supports","7.7 Rifampin or other Inducers of Cytochrome P450 3A4  ","Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. ","","ncit:positive","ncit:Qualitative","administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.\n\tadministration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.\n\tadministration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.","rifampin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"atorvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/aad8b373-0aec-4efb-8e61-3d8114b31127.html","2016-03-31 16:00:41 -0400","drug-drug-interaction","evidence-challenges","fluvastatin sodium extended-release tablets, 80 mg QD for 19 days  ↓2%  ↑27%      ","Data from drug-drug interaction studies involving fluvastatin and coadministration of either gemfibrozil, tolbutamide or losartan indicate that the PK disposition of either gemfibrozil, tolbutamide or losartan is not significantly altered when coadministered with fluvastatin","","ncit:negative","ncit:Qualitative","PK disposition of   losartan is not significantly altered when coadministered with fluvastatin.","losartan","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","fluvastatin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1fd0ba23-962e-427f-8b9d-2cf8f64d0f95.html","2016-03-31 14:25:54 -0400","drug-drug-interaction","evidence-challenges","   7.6 Fenofibrate  ","When CRESTOR was coadministered with fenofibrate, no clinically significant increase in the AUC of rosuvastatin or fenofibrate was observed. Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concomitant use of fenofibrates, caution should be used when prescribing fenofibrates with CRESTOR [seeWarnings and Precautions (5.1) andClinical Pharmacology (12.3)].","","ncit:negative","ncit:Qualitative","When CRESTOR was coadministered with fenofibrate, no clinically significant increase in the AUC of rosuvastatin or fenofibrate was observed. Study details in Section 12 Table 4","rosuvastatin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","fenofibrate","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/aad8b373-0aec-4efb-8e61-3d8114b31127.html","2016-03-31 12:59:13 -0700","drug-drug-interaction","evidence-challenges","fluvastatin sodium extended-release tablets, 80 mg QD for 19 days  ↓2%  ↑27%      ","Data from drug-drug interaction studies involving fluvastatin and coadministration of either gemfibrozil, tolbutamide or losartan indicate that the PK disposition of either gemfibrozil, tolbutamide or losartan is not significantly altered when coadministered with fluvastatin.","","ncit:negative","ncit:Qualitative","PK disposition of  gemfibrozil is not significantly altered when coadministered with fluvastatin.","gemfibrozil","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","fluvastatin","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 16:46:00 -0500","DDI-clinical-trial","evidence-supports","dose should be returned to the previous level.   ","Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. ","","ncit:positive","ncit:quantitative",,"P95","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","3","fluoxetine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","SD","Oral","1","BID","Oral","21","23","50","Percent","Decrease","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/2f44db39-e1d9-451e-ba31-e4b10366a430.html","2016-05-09 18:12:14 -0700","DDI-clinical-trial","evidence-supports"," metabolism. ","Concomitant administration of Zaleplon (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon. An initial dose of 5 mg should be given to patients who are concomitantly being treated with cimetidine (see DOSAGE AND ADMINISTRATION).","","ncit:positive","ncit:quantitative",,"zaleplon","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","10","cimetidine","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","800","UNK","UNK","UNK","UNK","Oral","UNK","UNK","85","Percent","Increase","UNK","UNK","UNK","85","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6.html","2016-03-14 17:06:08 -0400","DDI-clinical-trial","evidence-challenges","aripiprazole pharmacokinetics        ","The effects of ABILIFY on the exposures of other drugs are summarized in Figure 21. A population PK analysis in patients with major depressive disorder showed no substantial change in plasma concentrations of fluoxetine (20 mg/day or 40 mg/day), paroxetine CR (37.5 mg/day or 50 mg/day), or sertraline (100 mg/day or 150 mg/day) dosed to steady-state. The steady-state plasma concentrations of fluoxetine and norfluoxetine increased by about 18% and 36%, respectively, and concentrations of paroxetine decreased by about 27%. The steady-state plasma concentrations of sertraline and desmethylsertraline were not substantially changed when these antidepressant therapies were coadministered with aripiprazole.","","ncit:negative","ncit:quantitative","The steady-state plasma concentrations of sertraline and desmethylsertraline were not substantially changed when these antidepressant therapies were coadministered with aripiprazole.","desmethylsertraline","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","100-150","ABILIFY","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","Daily","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 14:47:05 -0500","DDI-clinical-trial","evidence-challenges","are coadministered; plasma level monitoring for digoxin is recommended.  ","Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.","","ncit:negative","ncit:quantitative",,"propranolol","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","triazole-dione","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","200","BID","Oral","5.5","BID","Oral","5.5","18","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2017-03-16 18:01:57 -0400","DDI-clinical-trial","evidence-supports"," — ","Administration of intramuscular lorazepam (2 mg) 1 hour after intramuscular olanzapine for injection (5 mg) did not significantly affect the pharmacokinetics of olanzapine, unconjugated lorazepam, or total lorazepam."," However, this co-administration of intramuscular","ncit:negative","ncit:quantitative","Formulation entered as IV but actually IM","olanzapine","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","5","lorazepam","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","2","SD","IV","1","SD","IV","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 16:38:11 -0500","DDI-clinical-trial","evidence-supports","elimination and cause increased blood levels.   ","Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.","","ncit:positive","ncit:quantitative",,"ketoconazole","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","P95","dikbD2R:metabolite","dikbD2R:object-drug-of-interaction","3","SD","Oral","1","BID","Oral","4","19","35","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e9481622-7cc6-418a-acb6-c5450daae9b0.html","2016-04-12 11:02:59 -0700","drug-drug-interaction","evidence-challenges","did not meaningfully alter the pharmacokinetics of apixaban .  ","In studies conducted in healthy subjects, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, atenolol, prasugrel, or acetylsalicylic acid.","","ncit:negative","ncit:Qualitative","pixaban did not meaningfully alter the pharmacokinetics of digoxin","digoxin","dikbD2R:active-ingredient","dikbD2R:object-drug-of-interaction","","apixaban","dikbD2R:active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
